1
|
Liu J, Vernikovskaya D, Bora G, Carlo A, Burchett W, Jordan S, Tang LWT, Yang J, Che Y, Chang G, Troutman MD, Di L. Novel Multiplexed High Throughput Screening of Selective Inhibitors for Drug-Metabolizing Enzymes Using Human Hepatocytes. AAPS J 2024; 26:36. [PMID: 38546903 DOI: 10.1208/s12248-024-00908-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2024] [Accepted: 03/07/2024] [Indexed: 04/02/2024] Open
Abstract
Selective chemical inhibitors are critical for reaction phenotyping to identify drug-metabolizing enzymes that are involved in the elimination of drug candidates. Although relatively selective inhibitors are available for the major cytochrome P450 enzymes (CYP), they are quite limited for the less common CYPs and non-CYPs. To address this gap, we developed a multiplexed high throughput screening (HTS) assay using 20 substrate reactions of multiple enzymes to simultaneously monitor the inhibition of enzymes in a 384-well format. Four 384-well assay plates can be run at the same time to maximize throughput. This is the first multiplexed HTS assay for drug-metabolizing enzymes reported. The HTS assay is technologically enabled with state-of-the-art robotic systems and highly sensitive modern LC-MS/MS instrumentation. Virtual screening is utilized to identify inhibitors for HTS based on known inhibitors and enzyme structures. Screening of ~4600 compounds generated many hits for many drug-metabolizing enzymes including the two time-dependent and selective aldehyde oxidase inhibitors, erlotinib and dibenzothiophene. The hit rate is much higher than that for the traditional HTS for biological targets due to the promiscuous nature of the drug-metabolizing enzymes and the biased compound selection process. Future efforts will focus on using this method to identify selective inhibitors for enzymes that do not currently have quality hits and thoroughly characterizing the newly identified selective inhibitors from our screen. We encourage colleagues from other organizations to explore their proprietary libraries using a similar approach to identify better inhibitors that can be used across the industry.
Collapse
Affiliation(s)
- Jianhua Liu
- Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research and Development, Groton, Connecticut, USA
| | - Daria Vernikovskaya
- Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research and Development, Groton, Connecticut, USA
| | - Gary Bora
- Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research and Development, Groton, Connecticut, USA
| | - Anthony Carlo
- Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research and Development, Groton, Connecticut, USA
| | - Woodrow Burchett
- Global Biometrics and Data Management, Pfizer Worldwide Research and Development, Groton, Connecticut, USA
| | - Samantha Jordan
- Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research and Development, Groton, Connecticut, USA
| | - Lloyd Wei Tat Tang
- Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research and Development, Groton, Connecticut, USA
| | - Joy Yang
- Medicinal Chemistry, Pfizer Worldwide Research and Development, Cambridge, Massachusetts, USA
| | - Ye Che
- Discovery Sciences, Pfizer Worldwide Research and Development, Groton, Connecticut, USA
| | - George Chang
- Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research and Development, Groton, Connecticut, USA
| | - Matthew D Troutman
- Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research and Development, Groton, Connecticut, USA
| | - Li Di
- Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research and Development, Groton, Connecticut, USA.
- Recursion Pharmaceuticals, Salt Lake City, UT, USA.
| |
Collapse
|
2
|
Liu T, Xu H, Amanullah S, Du Z, Hu X, Che Y, Zhang L, Jiang Z, Zhu L, Wang D. Deciphering the Enhancing Impact of Exogenous Brassinolide on Physiological Indices of Melon Plants under Downy Mildew-Induced Stress. Plants (Basel) 2024; 13:779. [PMID: 38592782 PMCID: PMC10974236 DOI: 10.3390/plants13060779] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/09/2024] [Revised: 03/04/2024] [Accepted: 03/06/2024] [Indexed: 04/11/2024]
Abstract
Melon (Cucumis melo L.) is a valuable horticultural crop of the Cucurbitaceae family. Downy mildew (DM), caused by Pseudoperonospora cubensis, is a significant inhibitor of the production and quality of melon. Brassinolide (BR) is a new type of phytohormone widely used in cultivation for its broad spectrum of resistance- and defense-mechanism-improving activity. In this study, we applied various exogenous treatments (0.5, 1.0, and 2.0 mg·L-1) of BR at four distinct time periods (6 h, 12 h, 24 h, and 48 h) and explored the impact of BR on physiological indices and the genetic regulation of melon seedling leaves infected by downy-mildew-induced stress. It was mainly observed that a 2.0 mg·L-1 BR concentration effectively promoted the enhanced photosynthetic activity of seedling leaves, and quantitative real-time polymerase chain reaction (qRT-PCR) analysis similarly exhibited an upregulated expression of the predicted regulatory genes of photosystem II (PSII) CmHCF136 (MELO3C023596.2) and CmPsbY (MELO3C010708.2), thus indicating the stability of the PSII reaction center. Furthermore, 2.0 mg·L-1 BR resulted in more photosynthetic pigments (nearly three times more than the chlorophyll contents (264.52%)) as compared to the control and other treatment groups and similarly upregulated the expression trend of the predicted key enzyme genes CmLHCP (MELO3C004214.2) and CmCHLP (MELO3C017176.2) involved in chlorophyll biosynthesis. Meanwhile, the maximum contents of soluble sugars and starch (186.95% and 164.28%) were also maintained, which were similarly triggered by the upregulated expression of the predicted genes CmGlgC (MELO3C006552.2), CmSPS (MELO3C020357.2), and CmPEPC (MELO3C018724.2), thereby maintaining osmotic adjustment and efficiency in eliminating reactive oxygen species. Overall, the exogenous 2.0 mg·L-1 BR exhibited maintained antioxidant activities, plastid membranal stability, and malondialdehyde (MDA) content. The chlorophyll fluorescence parameter values of F0 (42.23%) and Fv/Fm (36.67%) were also noticed to be higher; however, nearly three times higher levels of NPQ (375.86%) and Y (NPQ) (287.10%) were observed at 48 h of treatment as compared to all other group treatments. Increased Rubisco activity was also observed (62.89%), which suggested a significant role for elevated carbon fixation and assimilation and the upregulated expression of regulatory genes linked with Rubisco activity and the PSII reaction process. In short, we deduced that the 2.0 mg·L-1 BR application has an enhancing effect on the genetic modulation of physiological indices of melon plants against downy mildew disease stress.
Collapse
Affiliation(s)
- Tai Liu
- Daqing Branch of Heilongjiang Academy of Agricultural Sciences, Daqing 163711, China; (T.L.); (H.X.); (Z.D.); (X.H.); (Y.C.); (L.Z.); (Z.J.); (L.Z.)
| | - Huichun Xu
- Daqing Branch of Heilongjiang Academy of Agricultural Sciences, Daqing 163711, China; (T.L.); (H.X.); (Z.D.); (X.H.); (Y.C.); (L.Z.); (Z.J.); (L.Z.)
| | - Sikandar Amanullah
- College of Horticulture and Landscape Architecture, Northeast Agricultural University, Harbin 150030, China
- Key Laboratory of Biology and Genetic Improvement of Horticulture Crops (Northeast Region), Ministry of Agriculture and Rural Affairs, Northeast Agricultural University, Harbin 150030, China
| | - Zhiqiang Du
- Daqing Branch of Heilongjiang Academy of Agricultural Sciences, Daqing 163711, China; (T.L.); (H.X.); (Z.D.); (X.H.); (Y.C.); (L.Z.); (Z.J.); (L.Z.)
| | - Xixi Hu
- Daqing Branch of Heilongjiang Academy of Agricultural Sciences, Daqing 163711, China; (T.L.); (H.X.); (Z.D.); (X.H.); (Y.C.); (L.Z.); (Z.J.); (L.Z.)
| | - Ye Che
- Daqing Branch of Heilongjiang Academy of Agricultural Sciences, Daqing 163711, China; (T.L.); (H.X.); (Z.D.); (X.H.); (Y.C.); (L.Z.); (Z.J.); (L.Z.)
| | - Ling Zhang
- Daqing Branch of Heilongjiang Academy of Agricultural Sciences, Daqing 163711, China; (T.L.); (H.X.); (Z.D.); (X.H.); (Y.C.); (L.Z.); (Z.J.); (L.Z.)
| | - Zeyu Jiang
- Daqing Branch of Heilongjiang Academy of Agricultural Sciences, Daqing 163711, China; (T.L.); (H.X.); (Z.D.); (X.H.); (Y.C.); (L.Z.); (Z.J.); (L.Z.)
| | - Lei Zhu
- Daqing Branch of Heilongjiang Academy of Agricultural Sciences, Daqing 163711, China; (T.L.); (H.X.); (Z.D.); (X.H.); (Y.C.); (L.Z.); (Z.J.); (L.Z.)
| | - Di Wang
- Daqing Branch of Heilongjiang Academy of Agricultural Sciences, Daqing 163711, China; (T.L.); (H.X.); (Z.D.); (X.H.); (Y.C.); (L.Z.); (Z.J.); (L.Z.)
| |
Collapse
|
3
|
Chen J, Tang LWT, Jordan S, Harrison M, Gualtieri GM, DaSilva E, Morris D, Bora G, Che Y, Di L. Characterization of CYP3A5 Selective Inhibitors for Reaction Phenotyping of Drug Candidates. AAPS J 2024; 26:26. [PMID: 38366061 DOI: 10.1208/s12248-024-00894-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2023] [Accepted: 01/26/2024] [Indexed: 02/18/2024] Open
Abstract
CYP3A is one of the most important classes of enzymes and is involved in the metabolism of over 70% drugs. While several selective CYP3A4 inhibitors have been identified, the search for a selective CYP3A5 inhibitor has turned out to be rather challenging. Recently, several selective CYP3A5 inhibitors have been identified through high-throughput screening of ~ 11,000 compounds and hit expansion using human recombinant enzymes. We set forth to characterize the three most selective CYP3A5 inhibitors in a more physiologically relevant system of human liver microsomes to understand if these inhibitors can be used for reaction phenotyping studies in drug discovery settings. Gomisin A and T-5 were used as selective substrate reactions for CYP3A4 and CYP3A5 to determine IC50 values of the two enzymes. The results showed that clobetasol propionate and loteprednol etabonate were potent and selective CYP3A5 reversible inhibitors with selectivity of 24-fold against CYP3A4 and 39-fold or more against the other major CYPs. The selectivity of difluprednate in HLM is much weaker than that in the recombinant enzymes due to hydrolysis of the acetate group in HLM. Based on the selectivity data, loteprednol etabonate can be utilized as an orthogonal approach, when experimental fraction metabolized of CYP3A5 is greater than 0.5, to understand CYP3A5 contribution to drug metabolism and its clinical significance. Future endeavors to identify even more selective CYP3A5 inhibitors are warranted to enable accurate determination of CYP3A5 contribution to metabolism versus CYP3A4.
Collapse
Affiliation(s)
- Jie Chen
- Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research and Development, Cambridge, MA, USA
| | - Lloyd Wei Tat Tang
- Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research and Development, Groton, CT, USA
| | - Samantha Jordan
- Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research and Development, Groton, CT, USA
| | - Makayla Harrison
- Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research and Development, Groton, CT, USA
| | - Gabrielle M Gualtieri
- Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research and Development, Groton, CT, USA
| | - Ethan DaSilva
- Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research and Development, Groton, CT, USA
| | - Danial Morris
- Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research and Development, Groton, CT, USA
| | - Gary Bora
- Discovery Sciences, Pfizer Worldwide Research and Development, Groton, CT, USA
| | - Ye Che
- Discovery Sciences, Pfizer Worldwide Research and Development, Groton, CT, USA
| | - Li Di
- Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research and Development, Groton, CT, USA.
| |
Collapse
|
4
|
Nurmamat A, Hu Y, Mamatabdulla M, Che Y, Zhang LW, Zhang HP. [The effect of tumor spread through air spaces on the prognosis of patients with stage Ⅰ non-small cell lung cancer: a meta-analysis]. Zhonghua Yi Xue Za Zhi 2023; 103:3683-3690. [PMID: 38044614 DOI: 10.3760/cma.j.cn112137-20230730-00119] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/05/2023]
Abstract
Objective: To systematically evaluate the effect of tumor spread through air spaces (STAS) on the prognosis of patients with stage Ⅰ non-small cell lung cancer (NSCLC). Methods: PubMed, Embase, Web of Science, Cochrane Library, CNKI, Wanfang Database and VIP were searched to collect papers related to NSCLC and STAS published from the establishment of aboves databases to November 2022. Papers were screened according to the inclusion and exclusion criteria, and data were extracted. The 5-year overall survival (OS) and relapse-free survival (RFS) of stage Ⅰ NSCLC patients with or without STAS were compared. HR(95%CI) was used as effective indicator to evaluate the impact of STAS positivity on the prognosis of NSCLC. The quality of each included study was assessed using the Newcast-Ottawa Scale (NOS). Results: A total of 24 papers concerning 29 studies were included according to the inclusion and exclusion criteria, and there was no significant heterogeneity among the included papers(all I2<50%). A total of 10 883 patients with stage Ⅰ NSCLC were included in the studies, of which 3 298 (30.3%) were STAS-positive. The 29 studies showed that STAS-positive patients had a higher risk of 5-year recurrence than STAS-negative patients with stage Ⅰ NSCLC [HR=1.94(95%CI:1.74-2.16)];and a meta-analysis of 17 of the studies showed that that STAS-positive patients had a higher risk of 5-year death [HR=2.09 (95%CI:1.80-2.43)]. Compared with stage Ⅰ NSCLC patients who underwent other surgeries, STAS-positive patients who underwent sublobar resection had a higher risk of 5-year recurrence than patients with other procedures (HR=3.44, 95%CI: 2.49-4.76) and a higher risk of 5-year death (HR=3.40, 95%CI:2.05-5.64); and patients with stage Ⅰ NSCLC who had the pathologic histologic type of squamous carcinoma had a higher risk of 5-year recurrence (HR=2.48,95%CI:1.71-3.60) and a higher risk of 5-year death (HR=3.04, 95%CI: 1.90-4.86) than other patients with the type of squamous lung cancer. Conclusion: STAS positivity is a risk factor of poor prognosis in patients with stage Ⅰ NSCLC, especially for patients underwent sublobar resection or with squamous lung cancer.
Collapse
Affiliation(s)
- Abla Nurmamat
- Thoracic Surgery Center, the Eighth Affiliated Hospital of Xinjiang Medical University, Urumqi 830000, China
| | - Y Hu
- Department of Thoracic, First Affiliated Hospital of Xinjiang Medical University, Urumqi 830000, China
| | - Muradil Mamatabdulla
- Department of Thoracic, First Affiliated Hospital of Xinjiang Medical University, Urumqi 830000, China
| | - Y Che
- Thoracic Surgery Center, the Eighth Affiliated Hospital of Xinjiang Medical University, Urumqi 830000, China
| | - L W Zhang
- Department of Thoracic, First Affiliated Hospital of Xinjiang Medical University, Urumqi 830000, China
| | - H P Zhang
- Department of Thoracic, First Affiliated Hospital of Xinjiang Medical University, Urumqi 830000, China
| |
Collapse
|
5
|
Liu T, Amanullah S, Xu H, Gao P, Du Z, Hu X, Han M, Che Y, Zhang L, Qi G, Wang D. RNA-Seq Identified Putative Genes Conferring Photosynthesis and Root Development of Melon under Salt Stress. Genes (Basel) 2023; 14:1728. [PMID: 37761868 PMCID: PMC10530605 DOI: 10.3390/genes14091728] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2023] [Revised: 08/22/2023] [Accepted: 08/25/2023] [Indexed: 09/29/2023] Open
Abstract
Melon is an important fruit crop of the Cucurbitaceae family that is being cultivated over a large area in China. Unfortunately, salt stress has crucial effects on crop plants and damages photosynthesis, membranal lipid components, and hormonal metabolism, which leads to metabolic imbalance and retarded growth. Herein, we performed RNA-seq analysis and a physiological parameter evaluation to assess the salt-induced stress impact on photosynthesis and root development activity in melon. The endogenous quantification analysis showed that the significant oxidative damage in the membranal system resulted in an increased ratio of non-bilayer/bilayer lipid (MGDG/DGDG), suggesting severe irregular stability in the photosynthetic membrane. Meanwhile, root development was slowed down by a superoxidized membrane system, and downregulated genes showed significant contributions to cell wall biosynthesis and IAA metabolism. The comparative transcriptomic analysis also exhibited that major DEGs were more common in the intrinsic membrane component, photosynthesis, and metabolism. These are all processes that are usually involved in negative responses. Further, the WGCN analysis revealed the involvement of two main network modules: the thylakoid membrane and proteins related to photosystem II. The qRT-PCR analysis exhibited that two key genes (MELO3C006053.2 and MELO3C023596.2) had significant variations in expression profiling at different time intervals of salt stress treatments (0, 6, 12, 24, and 48 h), which were also consistent with the RNA-seq results, denoting the significant accuracy of molecular dataset analysis. In summary, we performed an extensive molecular and metabolic investigation to check the salt-stress-induced physiological changes in melon and proposed that the PSII reaction centre may likely be the primary stress target.
Collapse
Affiliation(s)
- Tai Liu
- Daqing Branch of Heilongjiang Academy of Agricultural Sciences, Daqing 163711, China; (T.L.); (H.X.); (Z.D.); (X.H.); (M.H.); (Y.C.); (L.Z.); (G.Q.)
| | - Sikandar Amanullah
- Key Laboratory of Biology and Genetic Improvement of Horticulture Crops (Northeast Region), Ministry of Agriculture and Rural Affairs, Northeast Agricultural University, Harbin 150030, China; (S.A.); (P.G.)
- College of Horticulture and Landscape Architecture, Northeast Agricultural University, Harbin 150030, China
| | - Huichun Xu
- Daqing Branch of Heilongjiang Academy of Agricultural Sciences, Daqing 163711, China; (T.L.); (H.X.); (Z.D.); (X.H.); (M.H.); (Y.C.); (L.Z.); (G.Q.)
| | - Peng Gao
- Key Laboratory of Biology and Genetic Improvement of Horticulture Crops (Northeast Region), Ministry of Agriculture and Rural Affairs, Northeast Agricultural University, Harbin 150030, China; (S.A.); (P.G.)
- College of Horticulture and Landscape Architecture, Northeast Agricultural University, Harbin 150030, China
| | - Zhiqiang Du
- Daqing Branch of Heilongjiang Academy of Agricultural Sciences, Daqing 163711, China; (T.L.); (H.X.); (Z.D.); (X.H.); (M.H.); (Y.C.); (L.Z.); (G.Q.)
| | - Xixi Hu
- Daqing Branch of Heilongjiang Academy of Agricultural Sciences, Daqing 163711, China; (T.L.); (H.X.); (Z.D.); (X.H.); (M.H.); (Y.C.); (L.Z.); (G.Q.)
| | - Mo Han
- Daqing Branch of Heilongjiang Academy of Agricultural Sciences, Daqing 163711, China; (T.L.); (H.X.); (Z.D.); (X.H.); (M.H.); (Y.C.); (L.Z.); (G.Q.)
| | - Ye Che
- Daqing Branch of Heilongjiang Academy of Agricultural Sciences, Daqing 163711, China; (T.L.); (H.X.); (Z.D.); (X.H.); (M.H.); (Y.C.); (L.Z.); (G.Q.)
| | - Ling Zhang
- Daqing Branch of Heilongjiang Academy of Agricultural Sciences, Daqing 163711, China; (T.L.); (H.X.); (Z.D.); (X.H.); (M.H.); (Y.C.); (L.Z.); (G.Q.)
| | - Guochao Qi
- Daqing Branch of Heilongjiang Academy of Agricultural Sciences, Daqing 163711, China; (T.L.); (H.X.); (Z.D.); (X.H.); (M.H.); (Y.C.); (L.Z.); (G.Q.)
| | - Di Wang
- Daqing Branch of Heilongjiang Academy of Agricultural Sciences, Daqing 163711, China; (T.L.); (H.X.); (Z.D.); (X.H.); (M.H.); (Y.C.); (L.Z.); (G.Q.)
| |
Collapse
|
6
|
Che Y, Gribenko AV, Song X, Handke LD, Efferen KS, Tompkins K, Kodali S, Nunez L, Prasad AK, Phelan LM, Ammirati M, Yu X, Lees JA, Chen W, Martinez L, Roopchand V, Han S, Qiu X, DeVincenzo JP, Jansen KU, Dormitzer PR, Swanson KA. Rational Design of a Highly Immunogenic Prefusion-Stabilized F Glycoprotein Antigen for a Respiratory Syncytial Virus Vaccine. Sci Transl Med 2023; 15:eade6422. [PMID: 37023209 DOI: 10.1126/scitranslmed.ade6422] [Citation(s) in RCA: 11] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/08/2023]
Abstract
Respiratory syncytial virus (RSV) is the leading, global cause of serious respiratory disease in infants and is an important cause of respiratory illness in older adults. No RSV vaccine is currently available. The RSV fusion (F) glycoprotein is a key antigen for vaccine development, and its prefusion conformation is the target of the most potent neutralizing antibodies. Here, we describe a computational and experimental strategy for designing immunogens that enhance the conformational stability and immunogenicity of RSV prefusion F. We obtained an optimized vaccine antigen after screening nearly 400 engineered F constructs. Through in vitro and in vivo characterization studies, we identified F constructs that are more stable in the prefusion conformation and elicit ~10-fold higher serum neutralizing titers in cotton rats than DS-Cav1. The stabilizing mutations of the lead construct (847) were introduced onto F glycoprotein backbones of strains representing the dominant circulating genotypes of the two major RSV subgroups, A and B. Immunization of cotton rats with a bivalent vaccine formulation of these antigens conferred complete protection against RSV challenge, with no evidence of disease enhancement. The resulting bivalent RSV prefusion F investigational vaccine has recently been shown to be efficacious against RSV disease in two pivotal phase 3 efficacy trials, one for passive protection of infants by immunization of pregnant women and the second for active protection of older adults by direct immunization.
Collapse
Affiliation(s)
- Ye Che
- Discovery Sciences, Pfizer Inc; Groton, CT 06340, USA
| | - Alexey V Gribenko
- Vaccine Research and Development, Pfizer Inc; Pearl River, NY 10965, USA
| | - Xi Song
- Discovery Sciences, Pfizer Inc; Groton, CT 06340, USA
| | - Luke D Handke
- Vaccine Research and Development, Pfizer Inc; Pearl River, NY 10965, USA
| | - Kari S Efferen
- Vaccine Research and Development, Pfizer Inc; Pearl River, NY 10965, USA
| | - Kristin Tompkins
- Vaccine Research and Development, Pfizer Inc; Pearl River, NY 10965, USA
| | - Srinivas Kodali
- Vaccine Research and Development, Pfizer Inc; Pearl River, NY 10965, USA
| | - Lorna Nunez
- Vaccine Research and Development, Pfizer Inc; Pearl River, NY 10965, USA
| | - A Krishna Prasad
- Vaccine Research and Development, Pfizer Inc; Pearl River, NY 10965, USA
| | - Lynn M Phelan
- Vaccine Research and Development, Pfizer Inc; Pearl River, NY 10965, USA
| | - Mark Ammirati
- Discovery Sciences, Pfizer Inc; Groton, CT 06340, USA
| | - Xiaodi Yu
- Discovery Sciences, Pfizer Inc; Groton, CT 06340, USA
| | - Joshua A Lees
- Discovery Sciences, Pfizer Inc; Groton, CT 06340, USA
| | - Wei Chen
- Vaccine Research and Development, Pfizer Inc; Pearl River, NY 10965, USA
| | - Lyndsey Martinez
- Vaccine Research and Development, Pfizer Inc; Pearl River, NY 10965, USA
| | - Vidia Roopchand
- Vaccine Research and Development, Pfizer Inc; Pearl River, NY 10965, USA
| | - Seungil Han
- Discovery Sciences, Pfizer Inc; Groton, CT 06340, USA
| | - Xiayang Qiu
- Discovery Sciences, Pfizer Inc; Groton, CT 06340, USA
| | - John P DeVincenzo
- Children's Foundation Research Institute at Le Bonheur Children's Hospital; Memphis, TN 38103, USA
| | - Kathrin U Jansen
- Vaccine Research and Development, Pfizer Inc; Pearl River, NY 10965, USA
| | - Philip R Dormitzer
- Vaccine Research and Development, Pfizer Inc; Pearl River, NY 10965, USA
| | - Kena A Swanson
- Vaccine Research and Development, Pfizer Inc; Pearl River, NY 10965, USA
| |
Collapse
|
7
|
Nestler T, Paffenholz P, Pfister D, Maatoug Y, Che Y, Hiester A, Albers P, Heidenreich A. Need for organ preservation in Postchemotherapy Retroperitoneal Lymph Node Dissection (PC-RPLND). Eur Urol 2023. [DOI: 10.1016/s0302-2838(23)00800-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
8
|
Che Y, Zuiverloon T, Arnout A, Vermeulen M, Pongratanakul P, Nettersheim D, Niegisch G, Albers P. PRIMETEST II – trial to test new predictors of recurrence in CS II A/B seminoma patients treated with primary robot-assisted retroperitoneal lymph node dissection. Eur Urol 2023. [DOI: 10.1016/s0302-2838(23)00574-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
9
|
Che Y, Luo Z, Cao Y, Sun N, Xue Q, He J. 1178P Integrated pathological analysis to develop a Gal-9 based immune survival stratification to predict the outcome of lung large cell neuroendocrine carcinoma. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1301] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
10
|
Farley KA, Koos MRM, Che Y, Horst R, Limberakis C, Bellenger J, Lira R, Gil-Silva LF, Gil RR. Cross-Linked Poly-4-Acrylomorpholine: A Flexible and Reversibly Compressible Aligning Gel for Anisotropic NMR Analysis of Peptides and Small Molecules in Water. Angew Chem Int Ed Engl 2021; 60:26314-26319. [PMID: 34609778 DOI: 10.1002/anie.202106794] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2021] [Indexed: 11/07/2022]
Abstract
Determination of the solution conformation of both small organic molecules and peptides in water remains a substantial hurdle in using NMR solution conformations to guide drug design due to the lack of easy to use alignment media. Herein we report the design of a flexible compressible chemically cross-linked poly-4-acrylomorpholine gel that can be used for the alignment of both small molecules and cyclic peptides in water. To test the new gel, residual dipolar couplings (RDCs) and J-coupling constants were used in the configurational analysis of strychnine hydrochloride, a molecule that has been studied extensively in organic solvents as well as a small cyclic peptide that is known to form an α-helix in water. The conformational ensembles for each molecule with the best fit to the data are reported. Identification of minor conformers in water that cannot easily be determined by conventional NOE measurements will facilitate the use of RDC experiments in structure-based drug design.
Collapse
Affiliation(s)
- Kathleen A Farley
- Medicinal Sciences, Pfizer, Eastern Point Road, Groton, CT, 06340, USA
| | - Martin R M Koos
- Department of Chemistry, Carnegie Mellon University, 4400 Fifth Avenue, Pittsburgh, PA, 15213, USA
| | - Ye Che
- Medicinal Sciences, Pfizer, Eastern Point Road, Groton, CT, 06340, USA
| | - Reto Horst
- Medicinal Sciences, Pfizer, Eastern Point Road, Groton, CT, 06340, USA
| | - Chris Limberakis
- Medicinal Sciences, Pfizer, Eastern Point Road, Groton, CT, 06340, USA
| | - Justin Bellenger
- Medicinal Sciences, Pfizer, Eastern Point Road, Groton, CT, 06340, USA
| | - Ricardo Lira
- Medicinal Sciences, Pfizer, Eastern Point Road, Groton, CT, 06340, USA
| | | | - Roberto R Gil
- Department of Chemistry, Carnegie Mellon University, 4400 Fifth Avenue, Pittsburgh, PA, 15213, USA
| |
Collapse
|
11
|
Farley KA, Koos MRM, Che Y, Horst R, Limberakis C, Bellenger J, Lira R, Gil‐Silva LF, Gil RR. Cross‐Linked Poly‐4‐Acrylomorpholine: A Flexible and Reversibly Compressible Aligning Gel for Anisotropic NMR Analysis of Peptides and Small Molecules in Water. Angew Chem Int Ed Engl 2021. [DOI: 10.1002/ange.202106794] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Affiliation(s)
| | - Martin R. M. Koos
- Department of Chemistry Carnegie Mellon University 4400 Fifth Avenue Pittsburgh PA 15213 USA
| | - Ye Che
- Medicinal Sciences Pfizer Eastern Point Road Groton CT 06340 USA
| | - Reto Horst
- Medicinal Sciences Pfizer Eastern Point Road Groton CT 06340 USA
| | - Chris Limberakis
- Medicinal Sciences Pfizer Eastern Point Road Groton CT 06340 USA
| | - Justin Bellenger
- Medicinal Sciences Pfizer Eastern Point Road Groton CT 06340 USA
| | - Ricardo Lira
- Medicinal Sciences Pfizer Eastern Point Road Groton CT 06340 USA
| | | | - Roberto R. Gil
- Department of Chemistry Carnegie Mellon University 4400 Fifth Avenue Pittsburgh PA 15213 USA
| |
Collapse
|
12
|
Abstract
The front pocket (FP) N-terminal cap (Ncap) cysteine is the most popular site of covalent modification in kinases. A long-standing hypothesis associates the Ncap position with cysteine hyper-reactivity; however, traditional computational predictions suggest that the FP Ncap cysteines are predominantly unreactive. Here we applied the state-of-the-art continuous constant pH molecular dynamics (CpHMD) to test the Ncap hypothesis. Simulations found that the Ncap cysteines of BTK/BMX/TEC/ITK/TXK, JAK3, and MKK7 are reactive to varying degrees; however, those of BLK and EGFR/ERBB2/ERBB4 possessing a Ncap+3 aspartate are unreactive. Analysis suggested that hydrogen bonding and electrostatic interactions drive the reactivity, and their absence renders the Ncap cysteine unreactive. To further test the Ncap hypothesis, we examined the FP Ncap+2 cysteines in JNK1/JNK2/JNK3 and CASK. Our work offers a systematic understanding of the cysteine structure-reactivity relationship and illustrates the use of CpHMD to differentiate cysteines toward the design of targeted covalent inhibitors with reduced chemical reactivities.
Collapse
Affiliation(s)
- Ruibin Liu
- Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, Maryland 21201, United States
| | - Shaoqi Zhan
- Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, Maryland 21201, United States
| | - Ye Che
- Discovery Sciences, Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Jana Shen
- Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, Maryland 21201, United States
| |
Collapse
|
13
|
Dong J, Che Y, Li H, Liu L, Shen D, Wang X, Sun X, Yang L. P56.06 Clinical Significance and Potential Function of S100A10 in Lung Adenocarcinoma. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.572] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
14
|
Yang CX, Zhao XH, Li YY, Zhou YF, Zhang LA, Yuan D, Xia W, Wang JM, Song JD, Lyu W, Luo YF, Jiang LF, Jiang L, Huang XC, Hu XY, Dong XJ, Cheng TY, Zhou YZ, Zhang Y, Che Y. [Incidence of unintended pregnancy within 2 years after delivery and its influencing factors in China]. Zhonghua Fu Chan Ke Za Zhi 2021; 56:616-621. [PMID: 34547862 DOI: 10.3760/cma.j.cn112141-20210611-00316] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To investigate the present situation of unintended pregnancy within two years postpartum and its influencing factors in China. Methods: Participants who delivered a live birth at 60 hospitals in 15 provinces in the eastern, central and western regions of China during July 2015 to June 2016 were interviewed by using structured questionnaire. Information on occurrence of unintended pregnancy within 2 years after delivery, postpartum contraceptive use, sexual resumption, breastfeeding, and women's socio-demographic characteristics, and so on, were collected. Life-table analysis, cluster log-rank tests and a 2-level Cox regression model were used for data analysis. Results: A total of 18 045 postpartum women were investigated. The cumulative 1- and 2-year unintended pregnancy rates after delivery were 5.3% (95%CI: 4.5%-6.1%) and 13.1% (95%CI: 11.3%-14.8%), respectively. Cox regression model analysis showed that the risk of unintended pregnancy within 2 years postpartum were increased in younger women, ethnic minorities, women with abortion history, and those who had a vaginal delivery with short lactation time and late postpartum contraceptive initiation (all P<0.01). The risk of postpartum unintended pregnancy was not associated with geographic regions and hospitals where women gave a birth (all P>0.05). Conclusions: In China, the risk of unintended pregnancy within 2 years after delivery is relatively high. Service institutions and service providers should improve the quality of postpartum family planning services, promote the use of high effect contraceptive methods, and educate women to use a method at the time of their sexual resumption or even before.
Collapse
Affiliation(s)
- C X Yang
- Department of Obstetrics, Tianjin Baodi Hospital, Tianjin 301800, China
| | - X H Zhao
- Shanghai Institute for Biomedical and Pharmaceutical Technologies, National Health Commission Key Laboratory of Reproduction Regulation, School of Public Health, Fudan University, Shanghai 200237, China
| | - Y Y Li
- Shanghai Institute for Biomedical and Pharmaceutical Technologies, National Health Commission Key Laboratory of Reproduction Regulation, School of Public Health, Fudan University, Shanghai 200237, China
| | - Y F Zhou
- Center for Maternal Health Care, Changsha Hosptial for Maternal and Child Health Care, Changsha 410007, China
| | - L A Zhang
- Department of Family Planning, Women Health Center of Shanxi, Taiyuan 030013, China
| | - D Yuan
- Department of Obstetrics and Gynecology, Tianjin Hedong District Obstetrics and Gynecology Hospital, Tianjin 300042, China
| | - W Xia
- Family Planning Research Institute, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
| | - J M Wang
- Department of Family Planning, The Second Hospital of Tianjin Medical University, Tianjin 300211, China
| | - J D Song
- Department of Obstetrics and Gynecology, Affiliated Hospital of Inner Mongolia Medical University, Hohhot 010059, China
| | - W Lyu
- Department of Gynecology, Tongde Hospital of Zhejiang Province, Hangzhou 310012, China
| | - Y F Luo
- Department of Reproductive Gynecology, Jilin Province Maternal and Child Health Hospital, Changchun 130051, China
| | - L F Jiang
- Research Center of Social Medicine, Henan Institute of Reproduction Health Science and Technology, Zhengzhou 450002, China
| | - L Jiang
- Research Center of Social Medicine, Henan Institute of Reproduction Health Science and Technology, Zhengzhou 450002, China
| | - X C Huang
- Department of Gynecology, Fujian Maternity and Children Health Hospital, Fuzhou 350001, China
| | - X Y Hu
- Department of Maternity Care, Shanghai Center for Women and Children's Health, Shanghai 200062, China
| | - X J Dong
- Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China
| | - T Y Cheng
- Department of Maternal Health Care, Maternal and Child Health Care Hospital of Urumqi, Urumqi 830000, China
| | - Y Z Zhou
- Department of Health Toxicology, School of Public Health, Zunyi Medical University, Zunyi 563006, China
| | - Y Zhang
- Shanghai Institute for Biomedical and Pharmaceutical Technologies, National Health Commission Key Laboratory of Reproduction Regulation, School of Public Health, Fudan University, Shanghai 200237, China
| | - Y Che
- Shanghai Institute for Biomedical and Pharmaceutical Technologies, National Health Commission Key Laboratory of Reproduction Regulation, School of Public Health, Fudan University, Shanghai 200237, China
| |
Collapse
|
15
|
Buddensieck C, Besser V, Che Y, Albers P, Schirren J, Sponholz S, Schirren M, Schauer A, Knoefel W, Hiester A. Discordant histology of abdominal and thoracic post chemotherapy residual tumor resection in patients with metastatic germ cell tumor. Eur Urol 2021. [DOI: 10.1016/s0302-2838(21)01042-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
16
|
Vogel AB, Kanevsky I, Che Y, Swanson KA, Muik A, Vormehr M, Kranz LM, Walzer KC, Hein S, Güler A, Loschko J, Maddur MS, Ota-Setlik A, Tompkins K, Cole J, Lui BG, Ziegenhals T, Plaschke A, Eisel D, Dany SC, Fesser S, Erbar S, Bates F, Schneider D, Jesionek B, Sänger B, Wallisch AK, Feuchter Y, Junginger H, Krumm SA, Heinen AP, Adams-Quack P, Schlereth J, Schille S, Kröner C, de la Caridad Güimil Garcia R, Hiller T, Fischer L, Sellers RS, Choudhary S, Gonzalez O, Vascotto F, Gutman MR, Fontenot JA, Hall-Ursone S, Brasky K, Griffor MC, Han S, Su AAH, Lees JA, Nedoma NL, Mashalidis EH, Sahasrabudhe PV, Tan CY, Pavliakova D, Singh G, Fontes-Garfias C, Pride M, Scully IL, Ciolino T, Obregon J, Gazi M, Carrion R, Alfson KJ, Kalina WV, Kaushal D, Shi PY, Klamp T, Rosenbaum C, Kuhn AN, Türeci Ö, Dormitzer PR, Jansen KU, Sahin U. BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Nature 2021; 592:283-289. [PMID: 33524990 DOI: 10.1038/s41586-021-03275-y] [Citation(s) in RCA: 395] [Impact Index Per Article: 131.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2020] [Accepted: 01/20/2021] [Indexed: 01/16/2023]
Abstract
A safe and effective vaccine against COVID-19 is urgently needed in quantities that are sufficient to immunize large populations. Here we report the preclinical development of two vaccine candidates (BNT162b1 and BNT162b2) that contain nucleoside-modified messenger RNA that encodes immunogens derived from the spike glycoprotein (S) of SARS-CoV-2, formulated in lipid nanoparticles. BNT162b1 encodes a soluble, secreted trimerized receptor-binding domain (known as the RBD-foldon). BNT162b2 encodes the full-length transmembrane S glycoprotein, locked in its prefusion conformation by the substitution of two residues with proline (S(K986P/V987P); hereafter, S(P2) (also known as P2 S)). The flexibly tethered RBDs of the RBD-foldon bind to human ACE2 with high avidity. Approximately 20% of the S(P2) trimers are in the two-RBD 'down', one-RBD 'up' state. In mice, one intramuscular dose of either candidate vaccine elicits a dose-dependent antibody response with high virus-entry inhibition titres and strong T-helper-1 CD4+ and IFNγ+CD8+ T cell responses. Prime-boost vaccination of rhesus macaques (Macaca mulatta) with the BNT162b candidates elicits SARS-CoV-2-neutralizing geometric mean titres that are 8.2-18.2× that of a panel of SARS-CoV-2-convalescent human sera. The vaccine candidates protect macaques against challenge with SARS-CoV-2; in particular, BNT162b2 protects the lower respiratory tract against the presence of viral RNA and shows no evidence of disease enhancement. Both candidates are being evaluated in phase I trials in Germany and the USA1-3, and BNT162b2 is being evaluated in an ongoing global phase II/III trial (NCT04380701 and NCT04368728).
Collapse
MESH Headings
- Aging/immunology
- Animals
- Antibodies, Neutralizing/immunology
- Antibodies, Viral/immunology
- Antigens, Viral/chemistry
- Antigens, Viral/genetics
- Antigens, Viral/immunology
- BNT162 Vaccine
- COVID-19/blood
- COVID-19/immunology
- COVID-19/prevention & control
- COVID-19/therapy
- COVID-19/virology
- COVID-19 Vaccines/administration & dosage
- COVID-19 Vaccines/chemistry
- COVID-19 Vaccines/genetics
- COVID-19 Vaccines/immunology
- Cell Line
- Clinical Trials as Topic
- Disease Models, Animal
- Female
- Humans
- Immunization, Passive
- Internationality
- Macaca mulatta/immunology
- Macaca mulatta/virology
- Male
- Mice
- Mice, Inbred BALB C
- Models, Molecular
- Protein Multimerization
- RNA, Viral/analysis
- Respiratory System/immunology
- Respiratory System/virology
- SARS-CoV-2/chemistry
- SARS-CoV-2/genetics
- SARS-CoV-2/immunology
- Solubility
- Spike Glycoprotein, Coronavirus/chemistry
- Spike Glycoprotein, Coronavirus/genetics
- Spike Glycoprotein, Coronavirus/immunology
- T-Lymphocytes/immunology
- Vaccination
- Vaccines, Synthetic/administration & dosage
- Vaccines, Synthetic/chemistry
- Vaccines, Synthetic/genetics
- Vaccines, Synthetic/immunology
- COVID-19 Serotherapy
- mRNA Vaccines
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | - Journey Cole
- Southwest National Primate Research Center, Texas Biomedical Research Institute, San Antonio, TX, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Olga Gonzalez
- Southwest National Primate Research Center, Texas Biomedical Research Institute, San Antonio, TX, USA
| | - Fulvia Vascotto
- TRON-Translational Oncology at the University Medical Centre of the Johannes Gutenberg University, Mainz, Germany
| | - Matthew R Gutman
- VCA SouthPaws Veterinary Specialists and Emergency Center, Fairfax, VA, USA
| | | | - Shannan Hall-Ursone
- Southwest National Primate Research Center, Texas Biomedical Research Institute, San Antonio, TX, USA
| | - Kathleen Brasky
- Southwest National Primate Research Center, Texas Biomedical Research Institute, San Antonio, TX, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Michal Gazi
- Texas Biomedical Research Institute, San Antonio, TX, USA
| | - Ricardo Carrion
- Southwest National Primate Research Center, Texas Biomedical Research Institute, San Antonio, TX, USA
| | | | | | - Deepak Kaushal
- Southwest National Primate Research Center, Texas Biomedical Research Institute, San Antonio, TX, USA
| | - Pei-Yong Shi
- University of Texas Medical Branch, Galveston, TX, USA
| | | | | | | | | | | | | | - Ugur Sahin
- BioNTech, Mainz, Germany.
- TRON-Translational Oncology at the University Medical Centre of the Johannes Gutenberg University, Mainz, Germany.
| |
Collapse
|
17
|
Liu Y, Heim KP, Che Y, Chi X, Qiu X, Han S, Dormitzer PR, Yang X. Prefusion structure of human cytomegalovirus glycoprotein B and structural basis for membrane fusion. Sci Adv 2021; 7:7/10/eabf3178. [PMID: 33674318 PMCID: PMC7935361 DOI: 10.1126/sciadv.abf3178] [Citation(s) in RCA: 30] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/18/2020] [Accepted: 01/21/2021] [Indexed: 05/12/2023]
Abstract
Human cytomegalovirus (HCMV) causes congenital disease with long-term morbidity. HCMV glycoprotein B (gB) transitions irreversibly from a metastable prefusion to a stable postfusion conformation to fuse the viral envelope with a host cell membrane during entry. We stabilized prefusion gB on the virion with a fusion inhibitor and a chemical cross-linker, extracted and purified it, and then determined its structure to 3.6-Å resolution by electron cryomicroscopy. Our results revealed the structural rearrangements that mediate membrane fusion and details of the interactions among the fusion loops, the membrane-proximal region, transmembrane domain, and bound fusion inhibitor that stabilized gB in the prefusion state. The structure rationalizes known gB antigenic sites. By analogy to successful vaccine antigen engineering approaches for other viral pathogens, the high-resolution prefusion gB structure provides a basis to develop stabilized prefusion gB HCMV vaccine antigens.
Collapse
Affiliation(s)
- Yuhang Liu
- Discovery Sciences, Pfizer Inc., Groton, CT 06340, USA.
| | - Kyle P Heim
- Vaccine Research and Development, Pfizer Inc., Pearl River, NY 10965, USA
| | - Ye Che
- Discovery Sciences, Pfizer Inc., Groton, CT 06340, USA
| | - Xiaoyuan Chi
- Vaccine Research and Development, Pfizer Inc., Pearl River, NY 10965, USA
| | - Xiayang Qiu
- Discovery Sciences, Pfizer Inc., Groton, CT 06340, USA
| | - Seungil Han
- Discovery Sciences, Pfizer Inc., Groton, CT 06340, USA
| | - Philip R Dormitzer
- Vaccine Research and Development, Pfizer Inc., Pearl River, NY 10965, USA.
| | - Xinzhen Yang
- Vaccine Research and Development, Pfizer Inc., Pearl River, NY 10965, USA
| |
Collapse
|
18
|
Schiemer J, Horst R, Meng Y, Montgomery JI, Xu Y, Feng X, Borzilleri K, Uccello DP, Leverett C, Brown S, Che Y, Brown MF, Hayward MM, Gilbert AM, Noe MC, Calabrese MF. Snapshots and ensembles of BTK and cIAP1 protein degrader ternary complexes. Nat Chem Biol 2020; 17:152-160. [PMID: 33199914 DOI: 10.1038/s41589-020-00686-2] [Citation(s) in RCA: 30] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2020] [Accepted: 09/30/2020] [Indexed: 02/05/2023]
Abstract
Heterobifunctional chimeric degraders are a class of ligands that recruit target proteins to E3 ubiquitin ligases to drive compound-dependent protein degradation. Advancing from initial chemical tools, protein degraders represent a mechanism of growing interest in drug discovery. Critical to the mechanism of action is the formation of a ternary complex between the target, degrader and E3 ligase to promote ubiquitination and subsequent degradation. However, limited insights into ternary complex structures exist, including a near absence of studies on one of the most widely co-opted E3s, cellular inhibitor of apoptosis 1 (cIAP1). In this work, we use a combination of biochemical, biophysical and structural studies to characterize degrader-mediated ternary complexes of Bruton's tyrosine kinase and cIAP1. Our results reveal new insights from unique ternary complex structures and show that increased ternary complex stability or rigidity need not always correlate with increased degradation efficiency.
Collapse
Affiliation(s)
- James Schiemer
- Discovery Sciences, Pfizer Worldwide Research and Development, Groton, CT, USA
| | - Reto Horst
- Discovery Sciences, Pfizer Worldwide Research and Development, Groton, CT, USA
| | - Yilin Meng
- Discovery Sciences, Pfizer Worldwide Research and Development, Groton, CT, USA
| | - Justin I Montgomery
- Discovery Sciences, Pfizer Worldwide Research and Development, Groton, CT, USA
| | - Yingrong Xu
- Discovery Sciences, Pfizer Worldwide Research and Development, Groton, CT, USA
| | - Xidong Feng
- Discovery Sciences, Pfizer Worldwide Research and Development, Groton, CT, USA
| | - Kris Borzilleri
- Discovery Sciences, Pfizer Worldwide Research and Development, Groton, CT, USA
| | - Daniel P Uccello
- Discovery Sciences, Pfizer Worldwide Research and Development, Groton, CT, USA
| | - Carolyn Leverett
- Discovery Sciences, Pfizer Worldwide Research and Development, Groton, CT, USA
| | - Stephen Brown
- Discovery Sciences, Pfizer Worldwide Research and Development, Groton, CT, USA
| | - Ye Che
- Discovery Sciences, Pfizer Worldwide Research and Development, Groton, CT, USA
| | - Matthew F Brown
- Discovery Sciences, Pfizer Worldwide Research and Development, Groton, CT, USA
| | - Matthew M Hayward
- Discovery Sciences, Pfizer Worldwide Research and Development, Groton, CT, USA
| | - Adam M Gilbert
- Discovery Sciences, Pfizer Worldwide Research and Development, Groton, CT, USA
| | - Mark C Noe
- Discovery Sciences, Pfizer Worldwide Research and Development, Groton, CT, USA
| | - Matthew F Calabrese
- Discovery Sciences, Pfizer Worldwide Research and Development, Groton, CT, USA.
| |
Collapse
|
19
|
Zhang C, Zhang G, Xue L, Zeng Q, Zhang Z, Luo Y, Wang F, Che Y, Zheng B, Yang Z, Xue Q, Sun N, He J. 1176P Expression and clinical significance of PD-L1 in small cell carcinoma of the esophagus. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1389] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
20
|
Wasilko DJ, Johnson ZL, Ammirati M, Che Y, Griffor MC, Han S, Wu H. Structural basis for chemokine receptor CCR6 activation by the endogenous protein ligand CCL20. Nat Commun 2020; 11:3031. [PMID: 32541785 PMCID: PMC7295996 DOI: 10.1038/s41467-020-16820-6] [Citation(s) in RCA: 55] [Impact Index Per Article: 13.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2020] [Accepted: 05/27/2020] [Indexed: 01/08/2023] Open
Abstract
Chemokines are important protein-signaling molecules that regulate various immune responses by activating chemokine receptors which belong to the G protein-coupled receptor (GPCR) superfamily. Despite the substantial progression of our structural understanding of GPCR activation by small molecule and peptide agonists, the molecular mechanism of GPCR activation by protein agonists remains unclear. Here, we present a 3.3-Å cryo-electron microscopy structure of the human chemokine receptor CCR6 bound to its endogenous ligand CCL20 and an engineered Go. CCL20 binds in a shallow extracellular pocket, making limited contact with the core 7-transmembrane (TM) bundle. The structure suggests that this mode of binding induces allosterically a rearrangement of a noncanonical toggle switch and the opening of the intracellular crevice for G protein coupling. Our results demonstrate that GPCR activation by a protein agonist does not always require substantial interactions between ligand and the 7TM core region. Chemokine receptors are GPCRs involved in immune responses and regulated by small protein ligands known as chemokines. A structural study of the human CCR6/CCL20–Go complex reveals that CCL20 binds in a shallow extracellular pocket, and suggests that activation of CCR6 by CCL20 binding involves an allosteric effect on a noncanonical toggle switch.
Collapse
Affiliation(s)
- David Jonathan Wasilko
- Discovery Sciences, Medicine Design, Pfizer Worldwide Research and Development, Groton, CT, 06340, USA
| | - Zachary Lee Johnson
- Discovery Sciences, Medicine Design, Pfizer Worldwide Research and Development, Groton, CT, 06340, USA
| | - Mark Ammirati
- Discovery Sciences, Medicine Design, Pfizer Worldwide Research and Development, Groton, CT, 06340, USA
| | - Ye Che
- Discovery Sciences, Medicine Design, Pfizer Worldwide Research and Development, Groton, CT, 06340, USA
| | - Matthew C Griffor
- Discovery Sciences, Medicine Design, Pfizer Worldwide Research and Development, Groton, CT, 06340, USA
| | - Seungil Han
- Discovery Sciences, Medicine Design, Pfizer Worldwide Research and Development, Groton, CT, 06340, USA
| | - Huixian Wu
- Discovery Sciences, Medicine Design, Pfizer Worldwide Research and Development, Groton, CT, 06340, USA.
| |
Collapse
|
21
|
Muk S, Ghosh S, Achuthan S, Chen X, Yao X, Sandhu M, Griffor MC, Fennell KF, Che Y, Shanmugasundaram V, Qiu X, Tate CG, Vaidehi N. Machine Learning for Prioritization of Thermostabilizing Mutations for G-Protein Coupled Receptors. Biophys J 2019; 117:2228-2239. [PMID: 31703801 DOI: 10.1016/j.bpj.2019.10.023] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2019] [Revised: 10/11/2019] [Accepted: 10/17/2019] [Indexed: 01/01/2023] Open
Abstract
Although the three-dimensional structures of G-protein coupled receptors (GPCRs), the largest superfamily of drug targets, have enabled structure-based drug design, there are no structures available for 87% of GPCRs. This is due to the stiff challenge in purifying the inherently flexible GPCRs. Identifying thermostabilized mutant GPCRs via systematic alanine scanning mutations has been a successful strategy in stabilizing GPCRs, but it remains a daunting task for each GPCR. We developed a computational method that combines sequence-, structure-, and dynamics-based molecular properties of GPCRs that recapitulate GPCR stability, with four different machine learning methods to predict thermostable mutations ahead of experiments. This method has been trained on thermostability data for 1231 mutants, the largest publicly available data set. A blind prediction for thermostable mutations of the complement factor C5a receptor 1 retrieved 36% of the thermostable mutants in the top 50 prioritized mutants compared to 3% in the first 50 attempts using systematic alanine scanning.
Collapse
Affiliation(s)
- Sanychen Muk
- Department of Computational and Quantitative Medicine, Beckman Research Institute of the City of Hope, Duarte, California
| | - Soumadwip Ghosh
- Department of Computational and Quantitative Medicine, Beckman Research Institute of the City of Hope, Duarte, California
| | - Srisairam Achuthan
- Department of Computational and Quantitative Medicine, Beckman Research Institute of the City of Hope, Duarte, California
| | | | - XiaoJie Yao
- Discovery Sciences, Pfizer, Groton, Connecticut
| | - Manbir Sandhu
- Department of Computational and Quantitative Medicine, Beckman Research Institute of the City of Hope, Duarte, California
| | | | | | - Ye Che
- Discovery Sciences, Pfizer, Groton, Connecticut
| | | | - Xiayang Qiu
- Discovery Sciences, Pfizer, Groton, Connecticut
| | | | - Nagarajan Vaidehi
- Department of Computational and Quantitative Medicine, Beckman Research Institute of the City of Hope, Duarte, California.
| |
Collapse
|
22
|
Yu X, Plotnikova O, Bonin PD, Subashi TA, McLellan TJ, Dumlao D, Che Y, Dong YY, Carpenter EP, West GM, Qiu X, Culp JS, Han S. Cryo-EM structures of the human glutamine transporter SLC1A5 (ASCT2) in the outward-facing conformation. eLife 2019; 8:e48120. [PMID: 31580259 PMCID: PMC6800002 DOI: 10.7554/elife.48120] [Citation(s) in RCA: 36] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2019] [Accepted: 10/02/2019] [Indexed: 12/17/2022] Open
Abstract
Alanine-serine-cysteine transporter 2 (ASCT2, SLC1A5) is the primary transporter of glutamine in cancer cells and regulates the mTORC1 signaling pathway. The SLC1A5 function involves finely tuned orchestration of two domain movements that include the substrate-binding transport domain and the scaffold domain. Here, we present cryo-EM structures of human SLC1A5 and its complex with the substrate, L-glutamine in an outward-facing conformation. These structures reveal insights into the conformation of the critical ECL2a loop which connects the two domains, thus allowing rigid body movement of the transport domain throughout the transport cycle. Furthermore, the structures provide new insights into substrate recognition, which involves conformational changes in the HP2 loop. A putative cholesterol binding site was observed near the domain interface in the outward-facing state. Comparison with the previously determined inward-facing structure of SCL1A5 provides a basis for a more integrated understanding of substrate recognition and transport mechanism in the SLC1 family.
Collapse
Affiliation(s)
- Xiaodi Yu
- Medicine DesignPfizer IncGrotonUnited States
| | | | | | | | | | | | - Ye Che
- Medicine DesignPfizer IncGrotonUnited States
| | - Yin Yao Dong
- Structural Genomics ConsortiumUniversity of OxfordOxfordUnited Kingdom
| | | | | | - Xiayang Qiu
- Medicine DesignPfizer IncGrotonUnited States
| | | | - Seungil Han
- Medicine DesignPfizer IncGrotonUnited States
| |
Collapse
|
23
|
Jiang T, Che Y, Seelman A, Guenin C, Khavari P. 401 Characterization of novel MAPK interactor with potential in therapeutic development. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.03.477] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
24
|
Farley KA, Che Y, Navarro-Vázquez A, Limberakis C, Anderson D, Yan J, Shapiro M, Shanmugasundaram V, Gil RR. Cyclic Peptide Design Guided by Residual Dipolar Couplings, J-Couplings, and Intramolecular Hydrogen Bond Analysis. J Org Chem 2019; 84:4803-4813. [PMID: 30605335 DOI: 10.1021/acs.joc.8b02811] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
Cyclic peptides have long tantalized drug designers with their potential ability to combine the best attributes of antibodies and small molecules. An ideal cyclic peptide drug candidate would be able to recognize a protein surface like an antibody while achieving the oral bioavailability of a small molecule. It has been hypothesized that such cyclic peptides balance permeability and solubility using their solvent-dependent conformational flexibility. Herein we report a conformational deconvolution NMR methodology that combines residual dipolar couplings, J-couplings, and intramolecular hydrogen bond analysis along with conformational analysis using molecular dynamics simulations and density functional theory calculations for studying cyclic peptide conformations in both low-dielectric solvent (chloroform) and high-dielectric solvent (DMSO) to experimentally study the solvent-dependent conformational change hypothesis. Taken together, the combined experimental and computational approaches can illuminate conformational ensembles of cyclic peptides in solution and help identify design opportunities for better permeability.
Collapse
Affiliation(s)
- Kathleen A Farley
- Medicinal Sciences, Pfizer Worldwide R&D , Eastern Point Road , Groton , Connecticut 06340 , United States
| | - Ye Che
- Medicinal Sciences, Pfizer Worldwide R&D , Eastern Point Road , Groton , Connecticut 06340 , United States
| | - Armando Navarro-Vázquez
- Departamento de Química Fundamental, CCEN , Universidade Federal de Pernambuco , Cidade Universitária, Recife , PE 50740-560 , Brazil
| | - Chris Limberakis
- Medicinal Sciences, Pfizer Worldwide R&D , Eastern Point Road , Groton , Connecticut 06340 , United States
| | - Dennis Anderson
- Medicinal Sciences, Pfizer Worldwide R&D , Eastern Point Road , Groton , Connecticut 06340 , United States
| | - Jiangli Yan
- Medicinal Sciences, Pfizer Worldwide R&D , Eastern Point Road , Groton , Connecticut 06340 , United States
| | - Michael Shapiro
- Medicinal Sciences, Pfizer Worldwide R&D , Eastern Point Road , Groton , Connecticut 06340 , United States
| | - Veerabahu Shanmugasundaram
- Medicinal Sciences, Pfizer Worldwide R&D , Eastern Point Road , Groton , Connecticut 06340 , United States
| | - Roberto R Gil
- Department of Chemistry , Carnegie Mellon University , Pittsburgh , Pennsylvania 15213 , United States
| |
Collapse
|
25
|
Abstract
Protein-protein interactions are ubiquitous, essential to almost all known biological processes, and offer attractive opportunities for therapeutic intervention. Linear peptide drugs, however, can be applied therapeutically as protein recognition motifs only to a limited extent because of their poor permeability, decreased receptor selectivity, and proteolytic stability. A major strategy in peptide chemistry is directed toward chemical modification and macrocyclization in order to limit a peptide's conformational possibilities, to increase its chemical and enzymatic stability, to prolong the time of action, and to increase activity and selectivity toward the receptor.
Collapse
Affiliation(s)
- Ye Che
- Discovery Sciences, Pfizer Inc., Groton, CT, USA.
| |
Collapse
|
26
|
Che Y, Taylor D, Luo D, Maldonado LY, Wang M, Wevill S, Vahdat H, Han X, Halpern V, Dorflinger L, Steiner MJ. Cohort study to evaluate efficacy, safety and acceptability of a two-rod contraceptive implant during third, fourth and fifth year of product use in China. Contracept X 2019; 1:100008. [PMID: 32494773 PMCID: PMC7252427 DOI: 10.1016/j.conx.2019.100008] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2018] [Revised: 05/08/2019] [Accepted: 05/14/2019] [Indexed: 11/26/2022] Open
Abstract
Objective Sino-implant (II) is a contraceptive implant approved for 4 years of use in China. We evaluated the contraceptive efficacy during the third, fourth and fifth year, and assessed additional pharmacokinetics (PK), safety, and acceptability endpoints. Study design We enrolled a cohort of 255 current Sino-Implant (II) users entering their third year and a second cohort of 243 users entering their fourth year. We followed these two cohorts for 12 and 24 months, respectively. To characterize PK endpoints (i.e. levonorgestrel (LNG), sex hormone binding globulin and free LNG index) over 5 years, we collected blood samples in a subset of 50 participants we followed during the third, fourth and fifth year. We also enrolled small cohorts (n = 20) of Sino-implant (II) users entering their sixth month and second year and followed them each for up to 6 months. Our primary efficacy measures were the pregnancy Pearl Indices during Year 3 and 4. Secondary objectives included assessments of PK, safety, acceptability and efficacy in the fifth year. Results We recorded four pregnancies, with a higher pregnancy rate during Year 3 [1.34 (95% CI: 0.28–3.93)] than Year 4 [0.44 (95% CI: 0.01–2.47)] or Year 5 [0.00 (95% CI: 0.00–2.02)]. The overall pregnancy rate for the third, fourth and fifth years of product use was 0.63 per 100 WY; 95% CI: (0.17–1.62). Mean LNG concentrations remained well above 200 pg/mL (Year 3 = 280.9; Year 4 = 233.6; Year 5 = 270.6). Most participants (93.7%) described their bleeding pattern as acceptable. Conclusion Sino-implant (II) is a highly effective contraceptive method in this population of Chinese women over 5 years. Implications Sino-implant (II) is a highly effective contraceptive method with an estimated Pearl Index of less than 1% over the third, fourth and fifth years of use in a population of Chinese women of reproductive age.
Collapse
Affiliation(s)
- Y Che
- Key Laboratory of Reproduction Regulation of NPFPC (SIPPR, IRD, Fudan University), Shanghai 200032, China
| | - D Taylor
- Contraceptive Technology Innovation Division, FHI 360, 359 Blackwell Street, Durham, NC 27701, USA
| | - D Luo
- Contraceptive Technology Innovation Division, FHI 360, 359 Blackwell Street, Durham, NC 27701, USA
| | - L Y Maldonado
- Contraceptive Technology Innovation Division, FHI 360, 359 Blackwell Street, Durham, NC 27701, USA
| | - M Wang
- Contraceptive Technology Innovation Division, FHI 360, 359 Blackwell Street, Durham, NC 27701, USA
| | - S Wevill
- Contraceptive Technology Innovation Division, FHI 360, 359 Blackwell Street, Durham, NC 27701, USA
| | - H Vahdat
- Contraceptive Technology Innovation Division, FHI 360, 359 Blackwell Street, Durham, NC 27701, USA
| | - X Han
- Henan Provincial Research Institute for Population and Family Planning, Henan, 450002, China
| | - V Halpern
- Contraceptive Technology Innovation Division, FHI 360, 359 Blackwell Street, Durham, NC 27701, USA
| | - L Dorflinger
- Contraceptive Technology Innovation Division, FHI 360, 359 Blackwell Street, Durham, NC 27701, USA
| | - M J Steiner
- Contraceptive Technology Innovation Division, FHI 360, 359 Blackwell Street, Durham, NC 27701, USA
| |
Collapse
|
27
|
Che Y, Gilbert AM, Shanmugasundaram V, Noe MC. Inducing protein-protein interactions with molecular glues. Bioorg Med Chem Lett 2018; 28:2585-2592. [DOI: 10.1016/j.bmcl.2018.04.046] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2018] [Revised: 04/16/2018] [Accepted: 04/18/2018] [Indexed: 12/27/2022]
|
28
|
Lopez-Pajares V, Bhaduri A, Garcia O, Guerrero A, Gowrishankar G, Che Y, Sanchez A, Boxer L, Gambhir S, Khavari P. 727 Metabolomic analysis reveals an essential role for glucose in epidermal differentiation. J Invest Dermatol 2018. [DOI: 10.1016/j.jid.2018.03.736] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
29
|
Abstract
Sequential randomness is one of the three important assumptions for Pulliam's vigilance model (1973). Here we tested the sequential randomness in Black-necked cranes Grus nigricollis, to see if the vigilance sequence can be predicted. Not similar to other recent studies, we found that most vigilance sequences (44/46) passed runs randomness test, and the length of an inter-scan interval was usually unrelated to its previous scan duration. Our findings suggest high predation risk might favor a random pattern of vigilance.
Collapse
Affiliation(s)
- Zhongqiu Li
- School of Life Sciences, Nanjing University,163 Xianlin Avenue, Nanjing, 210023, China.
| | - Ye Che
- School of Life Sciences, Nanjing University,163 Xianlin Avenue, Nanjing, 210023, China
| | - Le Yang
- Tibet Plateau Institute of Biology,19 Beijing West Road, Lhasa, 850000, China
| |
Collapse
|
30
|
Chen Q, Che Y, Wang Y, Kuang Y. Progestin primed mild stimulation in poor responders. Fertil Steril 2017. [DOI: 10.1016/j.fertnstert.2017.07.695] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
31
|
Che Y, Siprashvili Z, Kovalski J, Khavari P. 117 K-RAS oncogene activation is regulated by a snoRNA/SNARE protein axis that controls its subcellular transport. J Invest Dermatol 2017. [DOI: 10.1016/j.jid.2017.02.131] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
32
|
Thorarensen A, Dowty ME, Banker ME, Juba B, Jussif J, Lin T, Vincent F, Czerwinski RM, Casimiro-Garcia A, Unwalla R, Trujillo JI, Liang S, Balbo P, Che Y, Gilbert AM, Brown MF, Hayward M, Montgomery J, Leung L, Yang X, Soucy S, Hegen M, Coe J, Langille J, Vajdos F, Chrencik J, Telliez JB. Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans. J Med Chem 2017; 60:1971-1993. [DOI: 10.1021/acs.jmedchem.6b01694] [Citation(s) in RCA: 84] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Affiliation(s)
| | - Martin E. Dowty
- Pharmacokinetics, Dynamics, and Metabolism, Pfizer Worldwide R&D, 1 Burtt Road, Andover, Massachusetts 01810, United States
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Louis Leung
- Pharmacokinetics, Dynamics, and Metabolism, Pfizer Worldwide R&D, 1 Burtt Road, Andover, Massachusetts 01810, United States
| | - Xin Yang
- Pharmacokinetics, Dynamics, and Metabolism, Pfizer Worldwide R&D, 1 Burtt Road, Andover, Massachusetts 01810, United States
| | | | | | | | | | | | | | | |
Collapse
|
33
|
Cheng L, He X, Che Y, Che H, Qian M. Osteogenesis-promoting activity of composites SBA-15 mesoporous particles carrying oxytocin in vitro and in vivo. J BIOL REG HOMEOS AG 2017; 31:157-162. [PMID: 28337886] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
This study analyzes the performance of SBA-15 mesoporous particles carrying oxytocin (OT) in promoting osteogenesis in vitro and in vivo. The SBA-15 particles synthesized in the previous studies (about 30 μm in diameter and containing 10 nm deep pores) were loaded with the drug oxytocin and cultured with human osteosarcoma MG-63 cell line in vitro. The influence of particles on cell proliferation was studied. The level of the osteogenic marker (alkaline phosphatase and type I collagen) was measured. For in vivo studies, the connectivity defects of rabbit skull were prepared, and SBA-15 suspensions were regularly injected at the defect sites. The changes in the defect site calcium salt deposition were measured, and morphological changes were observed by microscopy. The material had to promote effect on osteogenesis-related indicators such as alkaline phosphatase and collagen I in bone sarcoma cell line MG-63. In vivo, the calcium salt deposition in OT/SBA-15 group was significantly higher than in the blank group. SBA-15 carriers appeared to persist in the region of the defect after the injection and release the drugs slowly, thus playing a more distinct role in promoting bone repair of local bone defects. The results showed that SBA-15 particles with OT could slow the release drugs and could help in promoting osteogenesis.
Collapse
Affiliation(s)
- L Cheng
- Department of Prosthodontics, School of Stomatology, Jilin University, Changchun, China
| | - X He
- Department of Prosthodontics, School of Stomatology, Jilin University, Changchun, China
| | - Y Che
- Department of Science and Education, School of Stomatology, Jilin University, Changchun, China
| | - H Che
- Department of Periodontics, School of Stomatology, Jilin University, Changchun, China
| | - M Qian
- Department of Prosthodontics, School of Stomatology, Jilin University, Changchun, China
| |
Collapse
|
34
|
Ahn K, Boehm M, Brown MF, Calloway J, Che Y, Chen J, Fennell KF, Geoghegan KF, Gilbert AM, Gutierrez JA, Kalgutkar AS, Lanba A, Limberakis C, Magee TV, O’Doherty I, Oliver R, Pabst B, Pandit J, Parris K, Pfefferkorn JA, Rolph TP, Patel R, Schuff B, Shanmugasundaram V, Starr JT, Varghese AH, Vera NB, Vernochet C, Yan J. Discovery of a Selective Covalent Inhibitor of Lysophospholipase-like 1 (LYPLAL1) as a Tool to Evaluate the Role of this Serine Hydrolase in Metabolism. ACS Chem Biol 2016; 11:2529-40. [PMID: 27391855 DOI: 10.1021/acschembio.6b00266] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
Lysophospholipase-like 1 (LYPLAL1) is an uncharacterized metabolic serine hydrolase. Human genome-wide association studies link variants of the gene encoding this enzyme to fat distribution, waist-to-hip ratio, and nonalcoholic fatty liver disease. We describe the discovery of potent and selective covalent small-molecule inhibitors of LYPLAL1 and their use to investigate its role in hepatic metabolism. In hepatocytes, selective inhibition of LYPLAL1 increased glucose production supporting the inference that LYPLAL1 is a significant actor in hepatic metabolism. The results provide an example of how a selective chemical tool can contribute to evaluating a hypothetical target for therapeutic intervention, even in the absence of complete biochemical characterization.
Collapse
Affiliation(s)
- Kay Ahn
- Cardiovascular, Metabolic, and Endocrine Diseases (CVMED) Research
Unit, Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry and §Pharmacokinetics, Dynamics, & Metabolism, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, United States
| | - Markus Boehm
- Cardiovascular, Metabolic, and Endocrine Diseases (CVMED) Research
Unit, Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry and §Pharmacokinetics, Dynamics, & Metabolism, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, United States
| | - Matthew F. Brown
- Cardiovascular, Metabolic, and Endocrine Diseases (CVMED) Research
Unit, Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry and §Pharmacokinetics, Dynamics, & Metabolism, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, United States
| | - Jessica Calloway
- Cardiovascular, Metabolic, and Endocrine Diseases (CVMED) Research
Unit, Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry and §Pharmacokinetics, Dynamics, & Metabolism, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, United States
| | - Ye Che
- Cardiovascular, Metabolic, and Endocrine Diseases (CVMED) Research
Unit, Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry and §Pharmacokinetics, Dynamics, & Metabolism, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, United States
| | - Jinshan Chen
- Cardiovascular, Metabolic, and Endocrine Diseases (CVMED) Research
Unit, Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry and §Pharmacokinetics, Dynamics, & Metabolism, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, United States
| | - Kimberly F. Fennell
- Cardiovascular, Metabolic, and Endocrine Diseases (CVMED) Research
Unit, Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry and §Pharmacokinetics, Dynamics, & Metabolism, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, United States
| | - Kieran F. Geoghegan
- Cardiovascular, Metabolic, and Endocrine Diseases (CVMED) Research
Unit, Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry and §Pharmacokinetics, Dynamics, & Metabolism, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, United States
| | - Adam M. Gilbert
- Cardiovascular, Metabolic, and Endocrine Diseases (CVMED) Research
Unit, Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry and §Pharmacokinetics, Dynamics, & Metabolism, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, United States
| | - Jemy A. Gutierrez
- Cardiovascular, Metabolic, and Endocrine Diseases (CVMED) Research
Unit, Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry and §Pharmacokinetics, Dynamics, & Metabolism, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, United States
| | - Amit S. Kalgutkar
- Cardiovascular, Metabolic, and Endocrine Diseases (CVMED) Research
Unit, Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry and §Pharmacokinetics, Dynamics, & Metabolism, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, United States
| | - Adhiraj Lanba
- Cardiovascular, Metabolic, and Endocrine Diseases (CVMED) Research
Unit, Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry and §Pharmacokinetics, Dynamics, & Metabolism, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, United States
| | - Chris Limberakis
- Cardiovascular, Metabolic, and Endocrine Diseases (CVMED) Research
Unit, Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry and §Pharmacokinetics, Dynamics, & Metabolism, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, United States
| | - Thomas V. Magee
- Cardiovascular, Metabolic, and Endocrine Diseases (CVMED) Research
Unit, Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry and §Pharmacokinetics, Dynamics, & Metabolism, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, United States
| | - Inish O’Doherty
- Cardiovascular, Metabolic, and Endocrine Diseases (CVMED) Research
Unit, Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry and §Pharmacokinetics, Dynamics, & Metabolism, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, United States
| | - Robert Oliver
- Cardiovascular, Metabolic, and Endocrine Diseases (CVMED) Research
Unit, Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry and §Pharmacokinetics, Dynamics, & Metabolism, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, United States
| | - Brandon Pabst
- Cardiovascular, Metabolic, and Endocrine Diseases (CVMED) Research
Unit, Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry and §Pharmacokinetics, Dynamics, & Metabolism, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, United States
| | - Jayvardhan Pandit
- Cardiovascular, Metabolic, and Endocrine Diseases (CVMED) Research
Unit, Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry and §Pharmacokinetics, Dynamics, & Metabolism, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, United States
| | - Kevin Parris
- Cardiovascular, Metabolic, and Endocrine Diseases (CVMED) Research
Unit, Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry and §Pharmacokinetics, Dynamics, & Metabolism, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, United States
| | - Jeffrey A. Pfefferkorn
- Cardiovascular, Metabolic, and Endocrine Diseases (CVMED) Research
Unit, Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry and §Pharmacokinetics, Dynamics, & Metabolism, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, United States
| | - Timothy P. Rolph
- Cardiovascular, Metabolic, and Endocrine Diseases (CVMED) Research
Unit, Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry and §Pharmacokinetics, Dynamics, & Metabolism, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, United States
| | - Rushi Patel
- Cardiovascular, Metabolic, and Endocrine Diseases (CVMED) Research
Unit, Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry and §Pharmacokinetics, Dynamics, & Metabolism, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, United States
| | - Brandon Schuff
- Cardiovascular, Metabolic, and Endocrine Diseases (CVMED) Research
Unit, Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry and §Pharmacokinetics, Dynamics, & Metabolism, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, United States
| | - Veerabahu Shanmugasundaram
- Cardiovascular, Metabolic, and Endocrine Diseases (CVMED) Research
Unit, Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry and §Pharmacokinetics, Dynamics, & Metabolism, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, United States
| | - Jeremy T. Starr
- Cardiovascular, Metabolic, and Endocrine Diseases (CVMED) Research
Unit, Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry and §Pharmacokinetics, Dynamics, & Metabolism, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, United States
| | - Alison H. Varghese
- Cardiovascular, Metabolic, and Endocrine Diseases (CVMED) Research
Unit, Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry and §Pharmacokinetics, Dynamics, & Metabolism, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, United States
| | - Nicholas B. Vera
- Cardiovascular, Metabolic, and Endocrine Diseases (CVMED) Research
Unit, Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry and §Pharmacokinetics, Dynamics, & Metabolism, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, United States
| | - Cecile Vernochet
- Cardiovascular, Metabolic, and Endocrine Diseases (CVMED) Research
Unit, Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry and §Pharmacokinetics, Dynamics, & Metabolism, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, United States
| | - Jiangli Yan
- Cardiovascular, Metabolic, and Endocrine Diseases (CVMED) Research
Unit, Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry and §Pharmacokinetics, Dynamics, & Metabolism, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, United States
| |
Collapse
|
35
|
Liang SH, Chen JM, Normandin MD, Chang JS, Chang GC, Taylor CK, Trapa P, Plummer MS, Para KS, Conn EL, Lopresti‐Morrow L, Lanyon LF, Cook JM, Richter KEG, Nolan CE, Schachter JB, Janat F, Che Y, Shanmugasundaram V, Lefker BA, Enerson BE, Livni E, Wang L, Guehl NJ, Patnaik D, Wagner FF, Perlis R, Holson EB, Haggarty SJ, El Fakhri G, Kurumbail RG, Vasdev N. Discovery of a Highly Selective Glycogen Synthase Kinase‐3 Inhibitor (PF‐04802367) That Modulates Tau Phosphorylation in the Brain: Translation for PET Neuroimaging. Angew Chem Int Ed Engl 2016. [DOI: 10.1002/ange.201603797] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- Steven H. Liang
- Gordon Center for Medical Imaging & Nuclear Medicine and Molecular Imaging Massachusetts General Hospital & Department of Radiology Harvard Medical School Boston MA 02114 USA
| | - Jinshan Michael Chen
- Pfizer Worldwide Research and Development, Groton Laboratories Eastern Point Road Groton CT 06340 USA
| | - Marc D. Normandin
- Gordon Center for Medical Imaging & Nuclear Medicine and Molecular Imaging Massachusetts General Hospital & Department of Radiology Harvard Medical School Boston MA 02114 USA
| | - Jeanne S. Chang
- Pfizer Worldwide Research and Development, Groton Laboratories Eastern Point Road Groton CT 06340 USA
| | - George C. Chang
- Pfizer Worldwide Research and Development, Groton Laboratories Eastern Point Road Groton CT 06340 USA
| | - Christine K. Taylor
- Pfizer Worldwide Research and Development, Groton Laboratories Eastern Point Road Groton CT 06340 USA
| | - Patrick Trapa
- Pfizer Worldwide Research and Development 610 Main Street Cambridge MA 02139 USA
| | - Mark S. Plummer
- Pfizer Worldwide Research and Development, Groton Laboratories Eastern Point Road Groton CT 06340 USA
| | - Kimberly S. Para
- Pfizer Worldwide Research and Development, Groton Laboratories Eastern Point Road Groton CT 06340 USA
| | - Edward L. Conn
- Pfizer Worldwide Research and Development, Groton Laboratories Eastern Point Road Groton CT 06340 USA
| | - Lori Lopresti‐Morrow
- Pfizer Worldwide Research and Development, Groton Laboratories Eastern Point Road Groton CT 06340 USA
| | - Lorraine F. Lanyon
- Pfizer Worldwide Research and Development, Groton Laboratories Eastern Point Road Groton CT 06340 USA
| | - James M. Cook
- Pfizer Worldwide Research and Development, Groton Laboratories Eastern Point Road Groton CT 06340 USA
| | - Karl E. G. Richter
- Pfizer Worldwide Research and Development, Groton Laboratories Eastern Point Road Groton CT 06340 USA
| | - Charlie E. Nolan
- Pfizer Worldwide Research and Development, Groton Laboratories Eastern Point Road Groton CT 06340 USA
| | - Joel B. Schachter
- Pfizer Worldwide Research and Development, Groton Laboratories Eastern Point Road Groton CT 06340 USA
| | - Fouad Janat
- Pfizer Worldwide Research and Development, Groton Laboratories Eastern Point Road Groton CT 06340 USA
| | - Ye Che
- Pfizer Worldwide Research and Development, Groton Laboratories Eastern Point Road Groton CT 06340 USA
| | | | - Bruce A. Lefker
- Pfizer Worldwide Research and Development 610 Main Street Cambridge MA 02139 USA
| | - Bradley E. Enerson
- Pfizer Worldwide Research and Development, Groton Laboratories Eastern Point Road Groton CT 06340 USA
| | - Elijahu Livni
- Gordon Center for Medical Imaging & Nuclear Medicine and Molecular Imaging Massachusetts General Hospital & Department of Radiology Harvard Medical School Boston MA 02114 USA
| | - Lu Wang
- Gordon Center for Medical Imaging & Nuclear Medicine and Molecular Imaging Massachusetts General Hospital & Department of Radiology Harvard Medical School Boston MA 02114 USA
| | - Nicolas J. Guehl
- Gordon Center for Medical Imaging & Nuclear Medicine and Molecular Imaging Massachusetts General Hospital & Department of Radiology Harvard Medical School Boston MA 02114 USA
| | - Debasis Patnaik
- Departments of Neurology & Psychiatry Massachusetts General Hospital Harvard Medical School 185 Cambridge Street Boston MA 02114 USA
| | - Florence F. Wagner
- Stanley Center for Psychiatric Research Broad Institute 415 Main Street Cambridge MA o2142 USA
| | - Roy Perlis
- Stanley Center for Psychiatric Research Broad Institute 415 Main Street Cambridge MA o2142 USA
- Departments of Neurology & Psychiatry Massachusetts General Hospital Harvard Medical School 185 Cambridge Street Boston MA 02114 USA
| | - Edward B. Holson
- Stanley Center for Psychiatric Research Broad Institute 415 Main Street Cambridge MA o2142 USA
| | - Stephen J. Haggarty
- Departments of Neurology & Psychiatry Massachusetts General Hospital Harvard Medical School 185 Cambridge Street Boston MA 02114 USA
| | - Georges El Fakhri
- Gordon Center for Medical Imaging & Nuclear Medicine and Molecular Imaging Massachusetts General Hospital & Department of Radiology Harvard Medical School Boston MA 02114 USA
| | - Ravi G. Kurumbail
- Pfizer Worldwide Research and Development, Groton Laboratories Eastern Point Road Groton CT 06340 USA
| | - Neil Vasdev
- Gordon Center for Medical Imaging & Nuclear Medicine and Molecular Imaging Massachusetts General Hospital & Department of Radiology Harvard Medical School Boston MA 02114 USA
| |
Collapse
|
36
|
Liang SH, Chen JM, Normandin MD, Chang JS, Chang GC, Taylor CK, Trapa P, Plummer MS, Para KS, Conn EL, Lopresti-Morrow L, Lanyon LF, Cook JM, Richter KEG, Nolan CE, Schachter JB, Janat F, Che Y, Shanmugasundaram V, Lefker BA, Enerson BE, Livni E, Wang L, Guehl NJ, Patnaik D, Wagner FF, Perlis R, Holson EB, Haggarty SJ, El Fakhri G, Kurumbail RG, Vasdev N. Discovery of a Highly Selective Glycogen Synthase Kinase-3 Inhibitor (PF-04802367) That Modulates Tau Phosphorylation in the Brain: Translation for PET Neuroimaging. Angew Chem Int Ed Engl 2016; 55:9601-5. [PMID: 27355874 PMCID: PMC4983481 DOI: 10.1002/anie.201603797] [Citation(s) in RCA: 58] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2016] [Indexed: 11/09/2022]
Abstract
Glycogen synthase kinase-3 (GSK-3) regulates multiple cellular processes in diabetes, oncology, and neurology. N-(3-(1H-1,2,4-triazol-1-yl)propyl)-5-(3-chloro-4-methoxyphenyl)oxazole-4-carboxamide (PF-04802367 or PF-367) has been identified as a highly potent inhibitor, which is among the most selective antagonists of GSK-3 to date. Its efficacy was demonstrated in modulation of tau phosphorylation in vitro and in vivo. Whereas the kinetics of PF-367 binding in brain tissues are too fast for an effective therapeutic agent, the pharmacokinetic profile of PF-367 is ideal for discovery of radiopharmaceuticals for GSK-3 in the central nervous system. A (11) C-isotopologue of PF-367 was synthesized and preliminary PET imaging studies in non-human primates confirmed that we have overcome the two major obstacles for imaging GSK-3, namely, reasonable brain permeability and displaceable binding.
Collapse
Affiliation(s)
- Steven H Liang
- Gordon Center for Medical Imaging & Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston, MA, 02114, USA
| | - Jinshan Michael Chen
- Pfizer Worldwide Research and Development, Groton Laboratories, Eastern Point Road, Groton, CT, 06340, USA
| | - Marc D Normandin
- Gordon Center for Medical Imaging & Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston, MA, 02114, USA
| | - Jeanne S Chang
- Pfizer Worldwide Research and Development, Groton Laboratories, Eastern Point Road, Groton, CT, 06340, USA
| | - George C Chang
- Pfizer Worldwide Research and Development, Groton Laboratories, Eastern Point Road, Groton, CT, 06340, USA
| | - Christine K Taylor
- Pfizer Worldwide Research and Development, Groton Laboratories, Eastern Point Road, Groton, CT, 06340, USA
| | - Patrick Trapa
- Pfizer Worldwide Research and Development, 610 Main Street, Cambridge, MA, 02139, USA
| | - Mark S Plummer
- Pfizer Worldwide Research and Development, Groton Laboratories, Eastern Point Road, Groton, CT, 06340, USA
| | - Kimberly S Para
- Pfizer Worldwide Research and Development, Groton Laboratories, Eastern Point Road, Groton, CT, 06340, USA
| | - Edward L Conn
- Pfizer Worldwide Research and Development, Groton Laboratories, Eastern Point Road, Groton, CT, 06340, USA
| | - Lori Lopresti-Morrow
- Pfizer Worldwide Research and Development, Groton Laboratories, Eastern Point Road, Groton, CT, 06340, USA
| | - Lorraine F Lanyon
- Pfizer Worldwide Research and Development, Groton Laboratories, Eastern Point Road, Groton, CT, 06340, USA
| | - James M Cook
- Pfizer Worldwide Research and Development, Groton Laboratories, Eastern Point Road, Groton, CT, 06340, USA
| | - Karl E G Richter
- Pfizer Worldwide Research and Development, Groton Laboratories, Eastern Point Road, Groton, CT, 06340, USA
| | - Charlie E Nolan
- Pfizer Worldwide Research and Development, Groton Laboratories, Eastern Point Road, Groton, CT, 06340, USA
| | - Joel B Schachter
- Pfizer Worldwide Research and Development, Groton Laboratories, Eastern Point Road, Groton, CT, 06340, USA
| | - Fouad Janat
- Pfizer Worldwide Research and Development, Groton Laboratories, Eastern Point Road, Groton, CT, 06340, USA
| | - Ye Che
- Pfizer Worldwide Research and Development, Groton Laboratories, Eastern Point Road, Groton, CT, 06340, USA
| | - Veerabahu Shanmugasundaram
- Pfizer Worldwide Research and Development, Groton Laboratories, Eastern Point Road, Groton, CT, 06340, USA
| | - Bruce A Lefker
- Pfizer Worldwide Research and Development, 610 Main Street, Cambridge, MA, 02139, USA
| | - Bradley E Enerson
- Pfizer Worldwide Research and Development, Groton Laboratories, Eastern Point Road, Groton, CT, 06340, USA
| | - Elijahu Livni
- Gordon Center for Medical Imaging & Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston, MA, 02114, USA
| | - Lu Wang
- Gordon Center for Medical Imaging & Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston, MA, 02114, USA
| | - Nicolas J Guehl
- Gordon Center for Medical Imaging & Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston, MA, 02114, USA
| | - Debasis Patnaik
- Departments of Neurology & Psychiatry, Massachusetts General Hospital, Harvard Medical School, 185 Cambridge Street, Boston, MA, 02114, USA
| | - Florence F Wagner
- Stanley Center for Psychiatric Research, Broad Institute, 415 Main Street, Cambridge, MA, o2142, USA
| | - Roy Perlis
- Stanley Center for Psychiatric Research, Broad Institute, 415 Main Street, Cambridge, MA, o2142, USA
- Departments of Neurology & Psychiatry, Massachusetts General Hospital, Harvard Medical School, 185 Cambridge Street, Boston, MA, 02114, USA
| | - Edward B Holson
- Stanley Center for Psychiatric Research, Broad Institute, 415 Main Street, Cambridge, MA, o2142, USA
| | - Stephen J Haggarty
- Departments of Neurology & Psychiatry, Massachusetts General Hospital, Harvard Medical School, 185 Cambridge Street, Boston, MA, 02114, USA
| | - Georges El Fakhri
- Gordon Center for Medical Imaging & Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston, MA, 02114, USA
| | - Ravi G Kurumbail
- Pfizer Worldwide Research and Development, Groton Laboratories, Eastern Point Road, Groton, CT, 06340, USA.
| | - Neil Vasdev
- Gordon Center for Medical Imaging & Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston, MA, 02114, USA.
| |
Collapse
|
37
|
Abstract
MicroRNAs (abbreviated miRNAs) have been demonstrated to be involved in tumorigenesis and cancer development and proposed as promising biomarkers in cancer diagnosis. Numerous studies have observed the aberrant expression of miRNAs in esophageal cancer. However, there are some discrepant results. Thus, we conducted this meta-analysis to identify the overall accuracy of miRNAs in the diagnosis of esophageal cancer. A comprehensive literature search was conducted in PubMed and other databases using combinations of key words. The summary receiver operator characteristic curves were plotted to assess the overall diagnostic performance of miRNAs. Chi-squared and I(2) tests were used to assess the heterogeneity between studies. Additionally, we conducted subgroup and sensitivity analyses to analyze the potential sources of heterogeneity. In total, 33 studies from 12 articles were available in this meta-analysis. The pooled sensitivity, specificity, positive and negative likelihood ratio (PLR, NLR) diagnostic odds ratio, and area under the curve were 0.80, 0.80, 4.0, 0.25, 16, and 0.87, respectively. Subgroup analyses based on the sample types (saliva-, serum- and plasma-based) showed no differences in the diagnostic accuracy of each subgroup. An independent meta-analysis of eight articles was conducted to evaluate the diagnostic accuracy of miRNAs in patients with esophageal squamous cell carcinoma, with a pooled sensitivity of 0.77, specificity of 0.83, PLR of 4.4, NLR of 0.27, diagnostic odds ratio of 16, and area under the curve of 0.87. In conclusion, this meta-analysis demonstrates the feasibility of using miRNAs as non-invasive biomarkers to discriminate esophageal cancer from healthy controls. However, further high-quality studies on more clearly defined esophageal cancer patient are needed to confirm our conclusion.
Collapse
Affiliation(s)
- J Wan
- Department of Thoracic Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, China
| | - W Wu
- Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei, China
| | - Y Che
- Department of Thoracic Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, China
| | - N Kang
- Department of Thoracic Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, China
| | - R Zhang
- Department of Thoracic Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, China
| |
Collapse
|
38
|
Lu Q, Yan S, Sun H, Wang W, Li Y, Yang X, Jiang X, Che Y, Xi Z. Akt inhibition attenuates rasfonin-induced autophagy and apoptosis through the glycolytic pathway in renal cancer cells. Cell Death Dis 2015; 6:e2005. [PMID: 26633711 PMCID: PMC4720880 DOI: 10.1038/cddis.2015.344] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2015] [Revised: 10/20/2015] [Accepted: 10/27/2015] [Indexed: 11/09/2022]
Abstract
Rasfonin is a fungal secondary metabolite with demonstrated antitumor effects. However, the underlying mechanism of the regulatory role in autophagy initiated by rasfonin is largely unknown. Moreover, the function of Akt to positively mediate the induced autophagy remains elusive. In the present study, we observed that rasfonin induced autophagy concomitant with the upregulation of Akt phosphorylation. Both the inhibition of Akt by small molecule inhibitors and genetic modification partially reduced rasfonin-dependent autophagic flux and PARP-1 cleavage. The overexpression of myrAkts (constant active form) promoted rasfonin-induced apoptosis and autophagy in a cell type- and Akt isoform-specific manner. Using quantitative PCR and immunoblotting, we observed that rasfonin increased the expression of glycolytic gene PFKFB3, and this increased expression can be suppressed in the presence of Akt inhibitor. The inhibition of PFKFB3 suppressed rasfonin-activated autophagy with enhanced PARP-1 cleavage. In the case of glucose uptake was disrupted, which mean the glycolytic pathway was fully blocked, the rasfonin-induced autophagy and PARP-1 cleavage were downregulated. Collectively, these results demonstrated that Akt positively regulated rasfonin-enhanced autophagy and caspase-dependent apoptosis primarily through affecting the glycolytic pathway.
Collapse
Affiliation(s)
- Q Lu
- State Key Laboratory of Mycology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China
- University of Chinese Academy of Sciences, Beijing, China
| | - S Yan
- State Key Laboratory of Mycology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China
- University of Chinese Academy of Sciences, Beijing, China
| | - H Sun
- State Key Laboratory of Mycology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China
- University of Chinese Academy of Sciences, Beijing, China
| | - W Wang
- State Key Laboratory of Mycology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China
- University of Chinese Academy of Sciences, Beijing, China
| | - Y Li
- State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, AMMS, Beijing, China
| | - X Yang
- Department of Urology, Peking University First Hospital, Beijing, China
| | - X Jiang
- State Key Laboratory of Mycology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China
| | - Y Che
- State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, AMMS, Beijing, China
| | - Z Xi
- Department of Urology, Peking University First Hospital, Beijing, China
| |
Collapse
|
39
|
Affiliation(s)
- Y Che
- Department of Ultrasound First Affiliated Hospital of Dalian Medical University Liaoning, China
| |
Collapse
|
40
|
Che Y, Jin S, Shi C, Wang L, Zhang X, Li Y, Baek JH. Treatment of Benign Thyroid Nodules: Comparison of Surgery with Radiofrequency Ablation. AJNR Am J Neuroradiol 2015; 36:1321-5. [PMID: 25814656 DOI: 10.3174/ajnr.a4276] [Citation(s) in RCA: 134] [Impact Index Per Article: 14.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2014] [Accepted: 12/17/2014] [Indexed: 11/07/2022]
Abstract
BACKGROUND AND PURPOSE Nodular goiter is one of the most common benign lesions in thyroid nodule. The main treatment of the disease is still the traditional surgical resection, however there are many problems such as general anesthesia, surgical scar, postoperative thyroid or parathyroid function abnormalities, and high nodules recurrence rate in residual gland. The purpose of this study was to compare the efficacy, safety, and cost-effectiveness of 2 treatment methods, surgery and radiofrequency ablation, for the treatment of benign thyroid nodules. MATERIALS AND METHODS From May 2012 to September 2013, 200 patients with nodular goiters who underwent surgery (group A) and 200 patients treated by radiofrequency ablation (group B) were enrolled in this study. Inclusion criteria were the following: 1) cosmetic problem, 2) nodule-related symptoms, 3) hyperfunctioning nodules related to thyrotoxicosis, and 4) refusal of surgery (for group B). An internally cooled radiofrequency ablation system and an 18-ga internally cooled electrode were used. We compared the 2 groups in terms of efficacy, safety, and cost-effectiveness during a 1-year follow-up. RESULTS After radiofrequency ablation, the nodule volume decreased significantly from 5.4 to 0.4 mL (P = .002) at the 12-month follow-up. The incidence of complications was significantly higher from surgery than from radiofrequency ablation (6.0% versus 1.0%, P = .002). Hypothyroidism was detected in 71.5% of patients after surgery but in none following radiofrequency ablation. The rate of residual nodules (11.9% versus 2.9%, P = .004) and hospitalization days was significantly greater after surgery (6.6 versus 2.1 days, P < .001), but the cost difference was not significant. CONCLUSIONS Surgical resection and radiofrequency ablation are both effective treatments of nodular goiter. Compared with surgery, the advantages of radiofrequency ablation include fewer complications, preservation of thyroid function, and fewer hospitalization days. Therefore, radiofrequency ablation should be considered a first-line treatment for benign thyroid nodules.
Collapse
Affiliation(s)
- Y Che
- From the Departments of Ultrasound (Y.C., L.W., X.Z.)
| | - S Jin
- Laparoscopic Surgery (S.J.)
| | - C Shi
- Pathology (C.S.), First Affiliated Hospital of Dalian Medical University, Dalian, China
| | - L Wang
- From the Departments of Ultrasound (Y.C., L.W., X.Z.)
| | - X Zhang
- From the Departments of Ultrasound (Y.C., L.W., X.Z.)
| | - Y Li
- College of Basic Medical Sciences and Institute of Cancer Stem Cell (Y.L.), Dalian Medical University, Dalian, China
| | - J H Baek
- Department of Radiology and Research Institute of Radiology (J.H.B.), University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
| |
Collapse
|
41
|
Flanagan ME, Abramite JA, Anderson DP, Aulabaugh A, Dahal UP, Gilbert AM, Li C, Montgomery J, Oppenheimer SR, Ryder T, Schuff BP, Uccello DP, Walker GS, Wu Y, Brown MF, Chen JM, Hayward MM, Noe MC, Obach RS, Philippe L, Shanmugasundaram V, Shapiro MJ, Starr J, Stroh J, Che Y. Chemical and computational methods for the characterization of covalent reactive groups for the prospective design of irreversible inhibitors. J Med Chem 2014; 57:10072-9. [PMID: 25375838 DOI: 10.1021/jm501412a] [Citation(s) in RCA: 211] [Impact Index Per Article: 21.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Interest in drugs that covalently modify their target is driven by the desire for enhanced efficacy that can result from the silencing of enzymatic activity until protein resynthesis can occur, along with the potential for increased selectivity by targeting uniquely positioned nucleophilic residues in the protein. However, covalent approaches carry additional risk for toxicities or hypersensitivity reactions that can result from covalent modification of unintended targets. Here we describe methods for measuring the reactivity of covalent reactive groups (CRGs) with a biologically relevant nucleophile, glutathione (GSH), along with kinetic data for a broad array of electrophiles. We also describe a computational method for predicting electrophilic reactivity, which taken together can be applied to the prospective design of thiol-reactive covalent inhibitors.
Collapse
Affiliation(s)
- Mark E Flanagan
- Center of Chemistry Innovation and Excellence, and ‡Department of Pharmacokinetics, Dynamics and Metabolism, Pfizer, Inc. , Eastern Point Road, Groton, Connecticut 06340, United States
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Hyung SJ, Feng X, Che Y, Stroh JG, Shapiro M. Detection of conformation types of cyclosporin retaining intramolecular hydrogen bonds by mass spectrometry. Anal Bioanal Chem 2014; 406:5785-94. [DOI: 10.1007/s00216-014-8023-1] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2014] [Revised: 07/02/2014] [Accepted: 07/07/2014] [Indexed: 11/24/2022]
|
43
|
Starr J, Brown MF, Aschenbrenner L, Caspers N, Che Y, Gerstenberger BS, Huband M, Knafels JD, Lemmon MM, Li C, McCurdy SP, McElroy E, Rauckhorst MR, Tomaras AP, Young JA, Zaniewski RP, Shanmugasundaram V, Han S. Siderophore Receptor-Mediated Uptake of Lactivicin Analogues in Gram-Negative Bacteria. J Med Chem 2014; 57:3845-55. [DOI: 10.1021/jm500219c] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Affiliation(s)
- Jeremy Starr
- Medicinal Chemistry, ⧧Computational Chemistry, §Antibacterials Research
Unit, and ¶Structural Biology, Pfizer Global Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Matthew F. Brown
- Medicinal Chemistry, ⧧Computational Chemistry, §Antibacterials Research
Unit, and ¶Structural Biology, Pfizer Global Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Lisa Aschenbrenner
- Medicinal Chemistry, ⧧Computational Chemistry, §Antibacterials Research
Unit, and ¶Structural Biology, Pfizer Global Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Nicole Caspers
- Medicinal Chemistry, ⧧Computational Chemistry, §Antibacterials Research
Unit, and ¶Structural Biology, Pfizer Global Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Ye Che
- Medicinal Chemistry, ⧧Computational Chemistry, §Antibacterials Research
Unit, and ¶Structural Biology, Pfizer Global Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Brian S. Gerstenberger
- Medicinal Chemistry, ⧧Computational Chemistry, §Antibacterials Research
Unit, and ¶Structural Biology, Pfizer Global Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Michael Huband
- Medicinal Chemistry, ⧧Computational Chemistry, §Antibacterials Research
Unit, and ¶Structural Biology, Pfizer Global Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - John D. Knafels
- Medicinal Chemistry, ⧧Computational Chemistry, §Antibacterials Research
Unit, and ¶Structural Biology, Pfizer Global Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - M. Megan Lemmon
- Medicinal Chemistry, ⧧Computational Chemistry, §Antibacterials Research
Unit, and ¶Structural Biology, Pfizer Global Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Chao Li
- Medicinal Chemistry, ⧧Computational Chemistry, §Antibacterials Research
Unit, and ¶Structural Biology, Pfizer Global Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Sandra P. McCurdy
- Medicinal Chemistry, ⧧Computational Chemistry, §Antibacterials Research
Unit, and ¶Structural Biology, Pfizer Global Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Eric McElroy
- Medicinal Chemistry, ⧧Computational Chemistry, §Antibacterials Research
Unit, and ¶Structural Biology, Pfizer Global Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Mark R. Rauckhorst
- Medicinal Chemistry, ⧧Computational Chemistry, §Antibacterials Research
Unit, and ¶Structural Biology, Pfizer Global Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Andrew P. Tomaras
- Medicinal Chemistry, ⧧Computational Chemistry, §Antibacterials Research
Unit, and ¶Structural Biology, Pfizer Global Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Jennifer A. Young
- Medicinal Chemistry, ⧧Computational Chemistry, §Antibacterials Research
Unit, and ¶Structural Biology, Pfizer Global Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Richard P. Zaniewski
- Medicinal Chemistry, ⧧Computational Chemistry, §Antibacterials Research
Unit, and ¶Structural Biology, Pfizer Global Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Veerabahu Shanmugasundaram
- Medicinal Chemistry, ⧧Computational Chemistry, §Antibacterials Research
Unit, and ¶Structural Biology, Pfizer Global Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Seungil Han
- Medicinal Chemistry, ⧧Computational Chemistry, §Antibacterials Research
Unit, and ¶Structural Biology, Pfizer Global Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| |
Collapse
|
44
|
Wakenhut F, Tran TD, Pickford C, Shaw S, Westby M, Smith-Burchnell C, Watson L, Paradowski M, Milbank J, Stonehouse D, Cheung K, Wybrow R, Daverio F, Crook S, Statham K, Leese D, Stead D, Adam F, Hay D, Roberts LR, Chiva JY, Nichols C, Blakemore DC, Goetz GH, Che Y, Gardner I, Dayal S, Pike A, Webster R, Pryde DC. The Discovery of Potent Nonstructural Protein 5A (NS5A) Inhibitors with a Unique Resistance Profile-Part 2. ChemMedChem 2014; 9:1387-96. [DOI: 10.1002/cmdc.201400046] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2014] [Indexed: 01/07/2023]
|
45
|
Gong Y, Song L, Yang C, Che Y, Chen Q, Wu B. The roles of mesenchymal stem cells in gastric lesion and regeneration: applications in gastric diseases. Acta Gastroenterol Belg 2013; 76:10-14. [PMID: 23650776] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
In recent years, many studies have focused on the roles of mesenchymal stem cells (MSCs) due to their contribution to tissue regeneration and tumorigenesis. However, the full profile of the roles of MSCs in gastric diseases has not been established. In this review, we aim to provide an overview on the roles of MSCs on cell lesion and regeneration in gastric diseases, including gastric ulcer, premalignant conditions and cancer. We will also discuss the mechanisms underlying the behaviors of MSCs in these diseases.
Collapse
Affiliation(s)
- Y Gong
- Gastrointestinal Department of Southern Building, PLA general hospital, Beijing, P.R. China
| | | | | | | | | | | |
Collapse
|
46
|
Fahnoe KC, Flanagan ME, Gibson G, Shanmugasundaram V, Che Y, Tomaras AP. Non-traditional antibacterial screening approaches for the identification of novel inhibitors of the glyoxylate shunt in gram-negative pathogens. PLoS One 2012; 7:e51732. [PMID: 23240059 PMCID: PMC3519852 DOI: 10.1371/journal.pone.0051732] [Citation(s) in RCA: 41] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2012] [Accepted: 11/08/2012] [Indexed: 01/06/2023] Open
Abstract
Antibacterial compounds that affect bacterial viability have traditionally been identified, confirmed, and characterized in standard laboratory media. The historical success of identifying new antibiotics via this route has justifiably established a traditional means of screening for new antimicrobials. The emergence of multi-drug-resistant (MDR) bacterial pathogens has expedited the need for new antibiotics, though many in the industry have questioned the source(s) of these new compounds. As many pharmaceutical companies' chemical libraries have been exhaustively screened via the traditional route, we have concluded that all compounds with any antibacterial potential have been identified. While new compound libraries and platforms are being pursued, it also seems prudent to screen the libraries we currently have in hand using alternative screening approaches. One strategy involves screening under conditions that better reflect the environment pathogens experience during an infection, and identifying in vivo essential targets and pathways that are dispensable for growth in standard laboratory media in vitro. Here we describe a novel screening strategy for identifying compounds that inhibit the glyoxylate shunt in Pseudomonas aeruginosa, a pathway that is required for bacterial survival in the pulmonary environment. We demonstrate that these compounds, which were not previously identified using traditional screening approaches, have broad-spectrum antibacterial activity when they are tested under in vivo-relevant conditions. We also show that these compounds have potent activity on both enzymes that comprise the glyoxylate shunt, a feature that was supported by computational homology modeling. By dual-targeting both enzymes in this pathway, we would expect to see a reduced propensity for resistance development to these compounds. Taken together, these data suggest that understanding the in vivo environment that bacterial pathogens must tolerate, and adjusting the antibacterial screening paradigm to reflect those conditions, could identify novel antibiotics for the treatment of serious MDR pathogens.
Collapse
Affiliation(s)
- Kelly C. Fahnoe
- Antibacterials Research Unit, Pfizer Worldwide Research & Development, Groton, Connecticut, United States of America
| | - Mark E. Flanagan
- Antibacterials Research Unit, Pfizer Worldwide Research & Development, Groton, Connecticut, United States of America
| | - Glenn Gibson
- Antibacterials Research Unit, Pfizer Worldwide Research & Development, Groton, Connecticut, United States of America
| | - Veerabahu Shanmugasundaram
- Antibacterials Research Unit, Pfizer Worldwide Research & Development, Groton, Connecticut, United States of America
| | - Ye Che
- Antibacterials Research Unit, Pfizer Worldwide Research & Development, Groton, Connecticut, United States of America
| | - Andrew P. Tomaras
- Antibacterials Research Unit, Pfizer Worldwide Research & Development, Groton, Connecticut, United States of America
- * E-mail:
| |
Collapse
|
47
|
Min S, Li L, Zhang M, Zhang Y, Liang X, Xie Y, He Q, Li Y, Sun J, Liu Q, Jiang X, Zhang Y, Che Y, Yang R. TGF-β-associated miR-27a inhibits dendritic cell-mediated differentiation of Th1 and Th17 cells by TAB3, p38 MAPK, MAP2K4 and MAP2K7. Genes Immun 2012; 13:621-31. [DOI: 10.1038/gene.2012.45] [Citation(s) in RCA: 50] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
|
48
|
McAllister LA, Montgomery JI, Abramite JA, Reilly U, Brown MF, Chen JM, Barham RA, Che Y, Chung SW, Menard CA, Mitton-Fry M, Mullins LM, Noe MC, O'Donnell JP, Oliver RM, Penzien JB, Plummer M, Price LM, Shanmugasundaram V, Tomaras AP, Uccello DP. Heterocyclic methylsulfone hydroxamic acid LpxC inhibitors as Gram-negative antibacterial agents. Bioorg Med Chem Lett 2012; 22:6832-8. [PMID: 23046961 DOI: 10.1016/j.bmcl.2012.09.058] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2012] [Revised: 09/04/2012] [Accepted: 09/17/2012] [Indexed: 11/19/2022]
Abstract
The synthesis and antibacterial activity of heterocyclic methylsulfone hydroxamates is presented. Compounds in this series are potent inhibitors of the LpxC enzyme, a key enzyme involved in the production of lipopolysaccharide (LPS) found in the outer membrane of Gram-negative bacteria. SAR evaluation of compounds in this series revealed analogs with potent antibacterial activity against challenging Gram-negative species such as Pseudomonas aeruginosa and Klebsiella pneumoniae.
Collapse
Affiliation(s)
- Laura A McAllister
- Pfizer Worldwide Research and Development, 445 Eastern Point Road, Groton, CT 06340, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Montgomery JI, Brown MF, Reilly U, Price LM, Abramite JA, Arcari J, Barham R, Che Y, Chen JM, Chung SW, Collantes EM, Desbonnet C, Doroski M, Doty J, Engtrakul JJ, Harris TM, Huband M, Knafels JD, Leach KL, Liu S, Marfat A, McAllister L, McElroy E, Menard CA, Mitton-Fry M, Mullins L, Noe MC, O'Donnell J, Oliver R, Penzien J, Plummer M, Shanmugasundaram V, Thoma C, Tomaras AP, Uccello DP, Vaz A, Wishka DG. Pyridone methylsulfone hydroxamate LpxC inhibitors for the treatment of serious gram-negative infections. J Med Chem 2012; 55:1662-70. [PMID: 22257165 DOI: 10.1021/jm2014875] [Citation(s) in RCA: 79] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
The synthesis and biological activity of a new series of LpxC inhibitors represented by pyridone methylsulfone hydroxamate 2a is presented. Members of this series have improved solubility and free fraction when compared to compounds in the previously described biphenyl methylsulfone hydroxamate series, and they maintain superior Gram-negative antibacterial activity to comparator agents.
Collapse
Affiliation(s)
- Justin I Montgomery
- Worldwide Medicinal Chemistry, Pfizer Worldwide Research and Development, 445 Eastern Point Road, Groton, Connecticut 06340, United States.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Brown MF, Reilly U, Abramite JA, Arcari JT, Oliver R, Barham RA, Che Y, Chen JM, Collantes EM, Chung SW, Desbonnet C, Doty J, Doroski M, Engtrakul JJ, Harris TM, Huband M, Knafels JD, Leach KL, Liu S, Marfat A, Marra A, McElroy E, Melnick M, Menard CA, Montgomery JI, Mullins L, Noe MC, O'Donnell J, Penzien J, Plummer MS, Price LM, Shanmugasundaram V, Thoma C, Uccello DP, Warmus JS, Wishka DG. Potent inhibitors of LpxC for the treatment of Gram-negative infections. J Med Chem 2012; 55:914-23. [PMID: 22175825 DOI: 10.1021/jm2014748] [Citation(s) in RCA: 69] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
In this paper, we present the synthesis and SAR as well as selectivity, pharmacokinetic, and infection model data for representative analogues of a novel series of potent antibacterial LpxC inhibitors represented by hydroxamic acid.
Collapse
Affiliation(s)
- Matthew F Brown
- Worldwide Medicinal Chemistry, Pfizer Global Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|